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ABSTRACT

Abstract
Pseudomonas aeruginosa and Staphylococcus aureus are
nosocomial opportunistic pathogens causing a wide variety of
both acute and chronic infections, such as pneumonia, bacteraemia,
and urinary tract infections. Immunocompromised patients and
those suffering cystic fibrosis show a particularly high susceptibility
to infection by these microorganisms. Moreover, the increasing
frequency of the isolation of multidrug-resistant bacteria (MDR) is
a major cause for concern.
Polymyxins are cyclic peptides with antimicrobial action
against Gram-negative bacteria that have been available since
1949, although they were left largely unused during the seventies
because of their nephrotoxicity and the availability of less toxic
antimicrobials to which bacteria had not yet developed resistance.
The most known polymyxin is colistin; like other cationic
polypeptides, colistin is an amphipathic compound and, it is
believed that this amphipathic nature is relevant to its activity
against bacteria.
Hence, the aim of this thesis was to synthesize antimicrobial
peptides inspired in colistin scaffold and explore their antimicrobial
activity against multidrug resistant bacteria such as P. aeruginosa and
S. aureus, determine possible synergistic interactions with commercial
xxiii
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antibiotics and explore their mechanisms of action.
Synthesis The main attempt in this first part was to
synthesize peptides in solid phase by the Fmoc/tBu method. After
synthesis, peptides were purified by preparative HPLC method and
finally, peptides were characterized by MALDI-TOF.
Antimicrobial activity This part focused on the study the
antimicrobial capacity of our peptides against multidrug resistant
bacteria, specially P. aeruginosa and S. aureus. First peptide (AMP38)
showed an acceptable antimicrobial activity against P. aureuginosa.
Moreover, several imipenem-resistant P. aeruginosa were tested with
AMP38 and imipenem showing a quite considerable synergistic
action, both with planktonic and sessile bacteria.
In addition, two peptides of the same family (CAMP113
and CAMP207) were tested against S. aureus (both planktonic and
sessile) showing a surprising antimicrobial action since Gram-positive
bacteria are regarding as naturally resistant to polymyxins. Moreover,
these peptides showed an inordinately high selectivity index.
Mechanisms of action The final part of this doctoral
thesis focused on an initial exploration of mechanisms of action
of peptides above mentioned. Transmission electronic microscopy
xxiv
Abstract
(TEM) assays were performed in order to elucidate possible
interactions between peptides and outer membrane of Gram-negative
bacteria. In addition, isothermal titration calorimetry assays were
carried out to determine peptide-teichoic acid interactions.
Data obtained from these studies are promising, being able
to be a therapeutic alternative for infections produced by multidrug
resistant bacteria.
xxv

RESUMEN

Resumen
Pseudomonas aeruginosa y Staphylococcus aureus son pato´genos
nosocomiales oportunistas causantes de una gran variedad de
infecciones tanto cro´nicas como agudas, tales como neumonı´a,
bacteriemia e infecciones del tracto urinario. Los pacientes
inmunocomprometidos y aquellos que padecen fibrosis quı´stica
muestran una susceptibilidad particularmente alta a infectarse por
estos microorganismos. Adema´s, la mayor frecuencia de aislamientos
de P. aeruginosa y S. aureus resistentes a mu´ltiples fa´rmacos (MDR)
es una causa importante de preocupacio´n.
Las polimixinas son pe´ptidos c´ıclicos con capacidad
antibio´tica contra las bacterias Gram-negativas que han estado
disponibles desde 1949, aunque se dejaron en gran parte de
usar durante los an˜os setenta debido a su nefrotoxicidad y a la
disponibilidad de otros antimicrobianos menos to´xicos a los cuales
las bacterias au´n no habı´an desarrollado resistencias. La polimixina
ma´s conocida es la colistina e, igual que otros polipe´ptidos
catio´nicos es un compuesto anfipa´tico. Se cree que esta naturaleza
anfipa´tica es relevante en su actividad contra las bacterias.
Por lo tanto, el objetivo de esta tesis fue sintetizar pe´ptidos
antimicrobianos inspirados en el esqueleto molecular de la colistina
y explorar su actividad antimicrobiana contra bacterias resistentes
xxix
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a mu´ltiples fa´rmacos como P. aeruginosa y S. aureus, determinar
posibles interacciones sine´rgicas con antibio´ticos comerciales y realizar
un primer acercamiento a sus mecanismos de accio´n.
Sı´ntesis
El principal objetivo de esta primera parte fue sintetizar
los pe´ptidos en fase so´lida por el me´todo Fmoc/tBu. Despue´s
de la s´ıntesis, los pe´ptidos se purificaron por el me´todo de
HPLC preprativo y, finalmente los pe´ptidos se caracterizaron por
MALDI-TOF.
Actividad antimicrobiana
Esta parte se centro´ en el estudio de la capacidad
antimicrobiana de nuestros pe´ptidos contra bacterias multirresistentes,
especialmente P. aeruginosa y S. aureus. El primer pe´ptido (AMP38)
mostro´ una actividad antimicrobiana aceptable frente a P. aeruginosa.
Adema´s, se probaron varias cepas de P. aeruginosa resistentes a
imipenem con AMP38 mostrando una actividad sine´rgica bastante
considerable, tanto en bacterias plancto´nicas como se´siles.
Adicionalmente, se realizaron ensayos con dos pe´ptidos de la
misma familia (CAMP113 y CAMP207) frente a S. aureus (tanto
xxx
Resumen
plancto´nicos como se´siles) mostrando una accio´n antimicrobiana
sorprendente, ya que las bacterias Gram-positivas como S. aureus se
consideran naturalmente resistentes a las polimixinas.
Mecanismos de accio´n
La parte final de esta tesis doctoral se centro´ en una
exploracio´n inicial de los mecanismos de accio´n de los pe´ptidos
mencionados anteriormente. Se realizaron ensayos de microscopı´a
electro´nica de transmisio´n (TEM) para aclarar las posibles
interacciones entre los pe´ptidos y la membrana externa de
las bacterias Gram-negativas. Adema´s, se realizaron ensayos de
calorimetr´ıa de titulacio´n isote´rmica para determinar las interacciones
pe´ptido-a´cido teicoico.
Los datos obtenidos de estos estudios son prometedores,
pudiendo ser una alternativa terape´utica para las infecciones
producidas por bacterias resistentes a mu´ltiples fa´rmacos.
xxxi

1 . INTRODUCTION

Introduction
1.1 Multidrug-resistant bacteria
Bacteria are the leading cause of infections worldwide,although they may affect individuals in different ways
particularly depending on social conditions, thus, in developed
and third world countries bacterial behaviour is different. Most
bacterial infections in the third world are those known as
“classical”, whereas in developed countries hospitalized patients
or individuals who have undergone medical treatments, such as
surgery, solid organ transplantation and anticancer treatments are
the most vulnerable. AIDS patients are quite similar to the last
ones. In recent years, the progressive increase in the incidence
of multidrug-resistance bacterial infections has raised concern. In
2014, the office of the President Obama published a detailed
report on antimicrobial resistance in the United States. Then, the
president published on September 18, an Executive Order entitled
“Combating Antibiotic-Resistant Bacteria”.1 This document included
sections on new policies, changes in funding for research focusing
this relevant public health challenge and recommendations, among
others. Following the election of Donald Trump, more than 30
scientific, social alliances and scientific societies signed a document
in which they expressed the hope these investments would be
3
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maintained and even expanded. Also in 2014, The World Health
Organization (WHO) published an extended report calling attention
to this crucial health problem.2 Bacterial resistance to antimicrobials
has likewise attracted the attention of the government of several
other countries, particularly the funding agency for European
research.
Nevertheless, antibiotics research had an erratic history.
The clinical use of antimicrobials started approximately in 1932,
with the release of Prontosil (an antibacterial drug discovered
at Bayer Laboratories, Germany), a molecule with a lethal
effect on gram-positive cocci. Prontosil was the first sulfamide
and it ushered in antibiotic era. Thereafter, new antibiotics
were rapidly discovered, including penicillin and streptomycin,
and became available for clinical use. Immediately research on
antimicrobials grew exponentially since both scientific community
and pharmaceuticals thought that infectious diseases may be
erradicated in a relatively short time.
Recently, due mostly to economic, rather than to medical
or scientific reasons, the pipeline of novel antimicrobial molecules
under development has mostly closed.3 Instead, most of the
antimicrobial drugs under development are improved derivates of
4
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Figure 1.1: Causes of death in the year 20504
those already on the market. This has had several non-negligible
consequences. Firstly, modified compounds, while frequently
enlarging the spectrum of drug activity or enhancing its
antimicrobial effect, do not change the target, including the
resistance mechanisms promoted in organisms exposed to these
agents. New molecules, acting through newly recognized mechanisms
of action and on different targets, are expected to be much more
effective, but very few have been developed over the past several
years. The recent emergence of new mechanisms of resistance, the
increased level of knowledge on these mechanisms, and the scarcity
of novel antimicrobial products able to target them account for
current growing concern and the revival of research efforts.
5
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The main sources of antibiotics discovered during the
golden era of antibiotics were soil bacteria and fungi. In
fact, antibiotics were long regarded as defence mechanisms of
soil bacteria, although this function has yet to be definitively
demonstrated in nature.5 Although the further exploration of
natural products for their antimicrobial activities is expensive and
the chance of successes limited, the identification of not previously
appreciated delivery methods or products, including those derived
from natural molecules, will open up new research perspectives
regarding antimicrobials.6
On the other hand, the World Health Organization (WHO)
released for first time ever a list of the highest priority needs for
new antibiotics.7 This list encloses 12 bacterial species:
Priority 1: Critical
1. Acinetobacter baumanii, carbapenem-resistant
2. Pseudomonas aeruginosa, carbapenem-resistant
3. Enterobacteriaceae, carbapenem-resistant, ESBL-producing
Priority 2: High
6
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4. Enterococcus faecium, vancomycin-resistant
5. Staphylococcus aureus, methicillin-resistant,
vancomycin-intermediate and resistant
6. Helicobacter pylori, clarithromycin-resistant
7. Campylobacter spp., fluoroquinolone-resistant
8. Salmonellae, fluoroquinolone-resistant
9. Neisseria gonorrhoeae, cephalosporin-resistant,
fluoroquinolone-resistant
Priority 3: Medium
10. Streptococcus pneumoniae, penicillin-non-susceptible
11. Haemophilus inﬂuenzae, ampicillin-resistant
12. Shigella spp., fluoroquinolone-resistant
The therapeutic options for these microorganisms are
extremely inadequate and the physicians are forced to prescribe
expensive drugs with significant side effects.8
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Moreover, other group of pathogens to take into acount is
the so-called ESKAPE pathogens (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas
aeruginosa and Enterobacter species). The proportion of these bacteria
in common urinary pulmonary, skin and bloodstream infections
has increased notably in recent years.9 Moreover, patients with
vascular prostheses, indwelling catheters, dialysis shunts, etc. are
particularly vulnerable to the virtually untreatable infections resulting
from ESKAPE colonization and subsequent biofilm formation.10
1.2 Respiratory infectious diseases
1.2.1 Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) encompasses
various low-airways disorders including emphysema. Periods of acute
bronchitis exacerbations with dyspnea, cough and purulent secretions
are common in patients. These exacerbations episodes are due to
infections in respiratory airways by bacteria, predominating three
species: Haemophilus inﬂuenzae, Streptococcus pneumoniae and Moraxella
catarrhalis.11 Moreover, it is often finding other species such as
8
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Pseudomonas aeruginosa and Staphylococcus aureus. This chronic presence
of bacteria in COPD patients leads in a lower lung development
in childhood, a chronic inflammatory response with lung damage
and a hypersensitivity caused by bacterial antigens.12
In the following sections, it will be deepened into bacterial
species.
1.2.2 Cystic Fibrosis
Cystic Fibrosis (CF) is an autosomal recessive disorder that
affects 70,000 individuals worldwide, primarily to Caucasians (high
prevalence in Europe, North America and Australia), although it
has been reported in all races and ethnicities.13 It is estimated that
1 out 5000 live births might be affected by CF in Europe, being
it the main common autosomal recessive disease in Europe.14 Lately,
median age survival in developed countries has increased until 40
years old, however in third world countries it remains very low.15
The first scientist who described CF was Dorothy Andersen
in 1938. She described CF as disease that affects pancreas,
nevertheless subsequently it was associated with lung infection as
9
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well.16 The disorder usually appears as an exocrine pancreatic
insufficiency, an increase in the Cl− concentration in sweat,
male infertility and airway illness that leads to progressive lung
dysfunction, which is the major cause of morbidity and mortality.17
Lung disease is characterized by chronic lung infection and
inflammation, leading to irreversible lung damage and finally, to
death.18 Nowadays, lung transplantation is the lass-resort option
treatment in order to cure CF patients.19
The malfunction is caused by mutations in a single gene on
the long arm of chromosome 7 that encodes a chloride-conducting
transmembrane protein (Cystic Fibrosis Transmembrane Regulator,
called CFTR).20 The main defect in CFTR channel involves
chloride and bicarbonate transport, besides CFTR interacts with
other ion channel such as the epithelial sodium channel (ENaC)
and also with another cellular pathways related to inflammation.21
Airway mucus is also dependant on the presence of bicarbonate
for normal function and reduced anion concentrations, increasing
viscosity in that mucus.22 CFTR dysfunction throws numerous
consequences to hydration, mucociliary clearance, mucus tethering
and innate immunity.23
More than 200 gene variants have been identified; these
10
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mutations have different effects on the manufacture of CFTR
proteins, its processing function and its stability at the cell
membrane.23 Historically, CFTR variants have been grouped into
six functional classes according to their effects on protein function.13
Classes I-III are related with ineffective CFTR function, patients
with these mutations have a severe phenotype. Whereas classes
IV-VI have some residual function of CFTR protein and have
mild lung phenotype and pancreatic sufficiency.24 Lately, it has
been proposed to be grouped in seven categories according to their
functional defect in order to optimize gene therapy.25 The most
common mutation (85% of patients worldwide), F508del (deletion
of phenylalanine at 508 residue)17, is a class II trafficking mutation,
approximately 3% of protein is trafficked to the cell membrane
where it is not functional.
The hypothesis that mutations in CFRT make epithelial cells
intrinsically more pro-inflammatory compared with healthy cells is
becoming more and more accepted.23, 26 Possibly, this inflammation
has a role in early life; when infection becomes regular and it is
also a chronic contributor to the airway microenvironment. Thus,
inflammation is the main pathology in the lung due to failure to
clear microorganisms (such as bacteria, fungi and viruses) and the
generation of a local toxic microenvironment.27
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Figure 1.2: Mutations of the CFTR gene. (Adapted from the
2016 Annual Data Report of the Cystic Fibrosis Foundation Patient
Registry, Bethesda, MD)15
1.2.3 Microbial infections in Cystic Fibrosis
In Children with CF, respiratory tract infections by
bacteria such as Staphylococcus aureus and Haemophilus inﬂuenzae
result in direct and indirect damage directly caused by the
inflammatory response to airway infection.28 When the disease
progresses, bronchiectasis develops, and sick individuals become
susceptible to a wide range of Gram-negative bacteria such as
Pseudomonas aeruginosa, the most predominant lung infectious agent
in CF patients. These microorganisms are ubiquitous in the
12
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environment and generally they are only associated with infection
in immunocompromised individuals.29 Other non-fermentative
Gram-negative bacteria are increasing their relevance in patients with
CF, among them, Stenotrophomonas maltophilia and Achromobacter
spp. All these Gram-negative bacteria have in common that they
acquire resistance to antibiotics easily.30 Burkholderia cepacia complex,
have been major pathogens in CF and are associated with increased
mortality.29 Moreover, some studies have identified a much greater
range of other bacteria in the airway, including obligate anaerobes.23
These studies suggest that bacterial diversity in lower airways is
associated with better lung function compared with a very high
abundance of one microorganism such as P. aeruginosa.31 For all
this, important questions are arising about use of antibiotics in a
prophylactic way, before children with CF are being seen with an
increased prevalence of P. aeruginosa.
Briefly, the most predominant bacterial species in CF,
although S. aureus and P. aeruginosa that are described extensively in
following chapters are:
Haemophilus influenzae: This organism is usually
unencapsulated (nontypeable). H. inﬂuenzae most frequently
infects CF patients in childhood persisting for an average of
13
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2 ½ months.32 Thus, it is one of the first colonizers to infect
individuals with CF.
Staphylococcus aureus: Historically was the first bacterium
found in CF respiratory disease specially in children. In addition,
some authors have proposed that S. aureus-infected patients may
experience more rapid decline in its pulmonary functions.33 Prior
to the advent of antibiotics, this organism was the major cause
of death in infants but with the beginning of the antibiotic era
was surpassed in prevalence by P. aeruginosa.16 Nonetheless, from
2000 to 2010 there was a significant increase in CF individuals
with methicillin-resistant S. aureus (MRSA). After 2010 prevalence
have plateaued due to infection prevention and control strategies.34
Pseudomonas aeruginosa: The most studied microorganism in
the context of CF because of it is the most common identified
in respiratory secretions of CF patients. Lately, the prevalence
of P. aeruginosa continues to decrease, it is believed that is due
to the implementation of therapy to eradicate initial acquisition.
Concurrently, the prevalence of multidrug-resistant P. aeruginosa
(MDR-PA) has remained constant.35
Burkholderia cepacia complex (BCC): BCC is a group
14
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of Gram-negative bacteria that is ubiquitous in the natural
environment. In recent times, BCC has achieved much notoriety for
its propensity to spread rapidly among CF patients. Additionally,
interpatient spread was recognized as a clinical trouble in 80’s.
Unlike H. inﬂuenzae and S. aureus, BCC often infects in more
advanced stages of the disease. Studies throw evidences that
BCC causes huge morbidity and mortality in CF, even more P.
aeruginosa.36
Other opportunistic pathogens such as Stenotrophomonas
maltophilia, Achromobacter xylosoxidans and Nontuberculosis
Mycobacteria have been found with increasing frequency in CF
cultures.
Aspergillus Species: These species are natural inhabitants of
soil, plants or decomposing organic matter.37 It is not uncommon
to find these fungi species in culture from respiratory tracts of
individuals with CF, reporting a prevalence of 9 to 57%.38, 39 The
most isolated strain is A. fumigatus following by A. niger, A. terreus,
A. versicolor and A. flavus.40
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Figure 1.3: Culture data seen in 2016 (Adapted from the 2016
Annual Data Report of the Cystic Fibrosis Foundation Patient
Registry, Bethesda, MD)15
1.3 Staphylococcus aureus
1.3.1 General points
S. aureus is one of the members of the genus Staphylococcus
(staphylococci) that tend to be arranged in grape-like clusters (from
the Greek “staphyle”, bunch of grapes), although it is possible
to see some single cells, pairs and short chains. They are
nonflagellate, nonmotile, and non-spore forming like all medically
important cocci. Staphylococci are facultative anaerobic, but it
16
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grows aerobically faster. Moreover S. aureus produces catalase and
it is the most virulent staphylococci because it has the ability
to form coagulases. Two of up-mentioned, coagulases are called
staphylocoagulase and von Willebrand factor (vWF), which are
responsible for transforming fibrinogen to fibrin.41, 42
S. aureus has a typical Gram-positive cell wall structure,
having peptidoglycan interspersed with considerable amounts of
teichoic acid and overlaid with polysaccharide and surface proteins.
The microorganism grown-up in blood agar produces white colonies
that tend to turn a buff-golden colour with time, that is why it
is called aureus.41 Most of the S. aureus present when cultured in
blood agar, a surrounding area of clear β-haemolysis.
In addition, S. aureus expresses a number of toxins (α, β,
δ), enzymes, adhesins and several surface proteins which together
promote the survival of this bacterium on tissues and other
substrates and protect it from elimination by the immune system.43
Briefly, α-toxin is the most important and the most well studied
toxin, being secreted by almost all strains of S. aureus.41 This
protein is a pore-forming β-barrel that lyses red blood cell and
leukocytes, but not neutrophils.43 After toxin inserts into the lipid
bilayer, critical molecules go out from the cell provoking death.
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Besides, S. aureus produces a bi-component toxin with similarity
to the α-toxin scaffold. It is called Panton-Valentine leucocidin
(PVL). Lately, this protein has been associated with infections
by community-associated methicillin-resistant S. aureus (CA-MRSA)
strains.42, 44 Another toxin is δ-cytotoxin, it has been classified as
a phenol-soluble modulin (PSM) that does not require a receptor
for its haemolytic activity. It is known that this toxin has multiple
function in pathogenesis.45 Moreover, PSM has showed non-specific
cytolytic activity and it may contribute to the allergic skin disease
atopic dermatitis by inducing mast cell degranulation.46 Finally,
β-toxin is a sphingomyelinase of type C; this molecule degrades
the sphingomyelin of the host cells causing cell lysis. This gene
encodes for this toxin is considered pathogenicity island thus it is
an important marker.47
Almost all enzymes secreted by S. aureus are proteases that
degrade host molecules provoking interferences in the signalling
cascades and leading tissue destruction.42
18
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1.3.2 Epidemiology
Among ten to thirty percent of the population is colonized
by S. aureus at any given time; in a hospital environment the
proportion increases considerably (hospital personnel and patients).41
The main habitat in human host is the anterior nares but it is
possible to find behind the nails or in the perianal area as well.
These bacteria attached to the nose are able to shed from the
skin and colonize other hosts or stay in fomites inasmuch as S.
aureus can stand long times in a very dry environment. Most of
the infections are in fact self-infections caused by strains carried in
nares or on the skin of the host.
In hospital environments, outbreaks caused by S. aureus
usually involve patients with wounds, surgical or other invasive
procedures or immunocompromised patients.41 In addition, one of
the most vulnerable groups are infants with less than 60 days old
because of exposure to pathogens in perinatal period and lack of
vaccine immunity.48
In the context of CF, S. aureus is the primary pathogen
colonizing the airways and in some times the host remains
colonized until the end of his life.49 Additionally, there is an
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increase in the number of isolates resistant to antimicrobial agents,
specially MRSA, in CF patients.50 Nowadays, the incidence of
staphylococcal colonization in CF patients needs more studies since
is still poorly recognized.51
Typically, S. aureus is divided in methicillin resistant (MRSA)
and methicillin sensitive (MSSA) this is useful to discriminate and
to improve the antimicrobial treatment. Multiple typing systems
have been developed for MSSA and MRSA including pulse-field
gel electrophoresis (PFGE), multilocus sequence typing (MLST),
and variable tandem repeat region of staphylococcal protein A
(spa typing). Moreover, MRSA isolates are discriminated by the
Staphylococcal Casette Chromosome (SCC)mec types which carries
the gene for methicillin resistance.52 Almost 80% of all S.
aureus isolates are resistant to penicillin and in addition, after the
introduction of methicillin in 1959 S. aureus developed resistance to
this antibiotic in just two years.52, 53
MRSA prevalence worldwide is very variable. For instance,
in Europe, less than 5% of all S. aureus are MRSA in the north
(Netherlands, Norway, Sweden and Denmark). On the other hand,
in southern Europe, this percentage increases inordinately until
25-50% (Portugal, Spain, Italy and Greece). Similar outcomes may
20
Introduction
be found in United States, where 50% of S. aureus are MRSA.
MRSA is endemic in Asia, it has the highest percentages of
MRSA worldwide. Up to 50% of S. aureus bloodstream infections
in certain regions of Asia are MRSA. Particularly, Korea and Japan
have the highest prevalence with >70% of all clinical isolates.
Moreover, other Asian nations have no official data but probably
prevalence is similarly to Korea or Japan. Since 2011, Australia
has accounted for 30-33% prevalence of MRSA from all S. aureus
isolates. Finally, in Africa we find quite variability; published data
are available for South Africa, Nigeria and countries from the
Mediterranean coast. Moreover, most of these studies come from
one single facility and identification was obtained by phenotypic
methods that are less effective. MRSA prevalence in these countries
is estimated around <25%. However, this prevalence has been
increasing since 2000s, although in South Africa prevalence is has
started to decrease due to infection control practices.54
1.3.3 Pathogenesis
In most cases, colonization precedes the progress of infection.
It is less common that infection occurs in the absence of known
S. aureus colonization. For instance, as a result of open wound or
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contamination of catheters.55
The leading stages of S. aureus attached are mediated by
a number of surface proteins that bind to cells by glycoprotein
fibronectin. Once S. aureus is attached to mammalian cells they
begin to produce α-toxin, thus causing injures to host cells. In
this moment, activity of host phagocytes is ineffective due to the
effect of protein A that binds IgG. Moreover, α-toxin continues
to destroy keratinocytes and other host cells favouring the lesion.
According the tissue involved, process may be different; in the case
of lungs, kidneys and other organs α-toxin action is astoundingly
destructive creating cavities and massive necrosis. At worst S. aureus
are not contained, spreading to the bloodstream, the bacterium
detach peptidoglycan activating massive complement response, this
response is the cause of leukopenia, thrombocytopenia and septic
shock.41
S. aureus has a big bunch of virulence factors that are
found on mobile genetic elements in most cases. Furthermore,
some of these virulence factor cannot be investigated because
they are human-specific, making their characterization difficult.56
Depending on the kind of infection and tissues involved, S.
aureus expresses and uses different virulence mechanisms. Briefly,
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S. aureus surface proteins such as Clumping factor A (ClfA),
Cumpling factor B (ClfB) and Fibronectin-binding protein A
(FnBPA) are involved in binding extracellular matrix proteins
enabling bacteria to attach to wound and multiply.57 Coagulase
proteins from S. aureus are responsible for the creation of a fibrin
capsule surrounding bacteria preventing leukocyte entrance.58 By the
formation of a polysaccharide microcapsule, S. aureus is able to
impede opsonization.59 Abscesses of S. aureus can be disrupted
releasing bacteria into bloodstream causing bacteraemia. These free
bacteria are almost impossible to be controlled; they can adhere to
endothelial surfaces provoking endocarditis among others.60
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These are some of the virulence factors involved in the
pathogenesis of S. aureus.61
• Membrane damaging toxins
• Cell wall-anchored proteins
– Clumping factor A (ClfA)
– Clumping factor B (ClfB)
– Fibronectin-binding protein A (FnBPA)
– SasX
– Protein A
– Iron regulated surface proteins
Since S. aureus is one of the earliest bacteria detected in
infants and children with CF, studies in this segment of the
population (peak prevalence between ages 11-15 years) acquire a
profound impact.62 In the las 10 years, it has been found
an overwhelming increase of MRSA isolates, especially in USA;52
some studies thrown a prevalence of S. aureus, both MRSA
and MSSA, of 43.2%.63 Notwithstanding, there is a continuous
debate about the significance of S. aureus in the pathogenesis
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of CF lung infection. It was believed that anti-staphylococcal
therapy has improved the longevity of the patients64 but some
recent studies have questioned the prophylactic anti-staphylococcal
antibiotics benefits.65
1.3.4 Adaptation
S. aureus adaptation, especially in lung, has been studied
widely; three of the most common strategies are small
colony-variants, hypermutable phenotype and persisters.
Small-colony variants (SCVs) are very common and observed
in CF patients. SCVs have a very slow growth rate, reduced
expression of haemolysins and loss of pigmentation, instead they
have an increased resistance to aminoglycosides and they are
able to persist after non-professional phagocytosis.66 Due to
the number of mutations in metabolic genes SVCs have a
deficiency in electron transport and they are auxotrophic for both
menadione or haemin.67 Their molecular characterisation reveals
that SVCs are lack in the expression of the virulence factor
agr.68 In CF patients, most of the SVCs are auxotrophic for
thymidine (TD-SCV), and it is believed that the reason is a long
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term trimethoprim-sulphomethoxazol treatment.69 Nonetheless, it is
assumed that thymidine is very abundant in airway secretions of
CF patients and can balance this thymidine auxotrophy.70
Hypermutable phenotype is one of the key processes in
resistance to antibiotics. Those hypermutable bacteria present a
mutation ratio much higher than normal counterpart, this mutation
lead the adaptation in stressful environments.66 This phenotype is
caused (in the most part) by defect in mutS or mutL genes that
lead in a methyl-directed mismatch repair system malfunction. Some
authors throw that this mutation frequency do not contribute
significantly to the antibiotic resistance developing in S. aureus.71 On
the other hand, another study shows that it has found more S.
aureus hypermutable strains in CF patients compared to non-CF
isolates.72 In recent past, the up mentioned thymidine-dependant
SCV isolates was pointed to be associated with hypermutability.73
Persisters were described in 1944 by Joseph Bigger. He
found that after treating with penicillin a growing population of
Staphylococcus spp., a small number of persisters cells survived.74
Nowadays, persisters are defined as “a small subpopulation of
bacteria that survive lethal concentrations of antibiotics without any
specific resistance mechanism”.75 These isolates are not drug-resistant
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mutants nay; they have a phenotypic switch that can revert to
wild-type easily.
Main resistance mechanisms, such as target modification by
both mutation or specialized enzymatic changes, target substitution,
modification or destruction of antibiotics, restricted permeability to
antibiotics, antibiotic efflux, among others, are widely studied and
understood, more details will be forthcoming in the next sections.
Nonetheless, persisters have tolerance to antibiotics. It is believed
that its metabolism is dormant thus, there is not interaction
between antibiotic and persister cell. Becoming a persister has the
handicap to the bacterium that they are not able to proliferate.75
1.4 Pseudomonas aeruginosa
1.4.1 General points
Pseudomonas aeruginosa is a respiratory, motile, Gram-negative
rod and it can produce several different water-soluble pigments.
Pyocyanin (blue pigment) is produced only by P. aeruginosa;
fluorescin (yellow pigment) is shared with other free-living
non-pathogenic Pseudomonas species. When these pigments are
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Figure 1.4: Transmission electron microscopy (TEM) image of P.
aeruginosa
combined produce the characteristic most well-known green
pigment. P. aeruginosa is able to growth in absence of oxygen
if nitrate is present as an electron acceptor.41 It has a wide
temperature range of survival (20 − 42◦C) and it can growth in
a high salt concentration medium as well. P. aeruginosa emits
a characteristic intense “fruity” non-disagreeable odour. As all
Gram-negative bacteria, P. aeruginosa has lipopolysaccharide (LPS)
in its outer membrane. Moreover, alginate is a copolymer formed
by mannuronic and glucuronic acids which is secreted by some
P. aeruginosa strains. Mutants that produce a huge amount of
alginate are the principal burden in CF patients.
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P. aeruginosa secretes multiple extracellular products as well,
such as exotoxin A (ExoA), elastase and Exoenzyme S (ExoS).
Exotoxin (ExoA) is the most toxic virulence factor of
P. aeruginosa, which has enzymatic activity. It belongs to the
mono-ADP-ribosyltransferase family and is composed by A domain
which is the responsible of the enzymatic activity and a B domain
responsible of binding.76 Invasive and locally destructive lesions are
due to the action of ExoA.77
Elastase is another major virulence factor in P. aeruginosa
and it is secreted by non-mucoid strains. This protein acts on
biologically important substrates such as elastin, human IgA and
IgG, complement and collagen.78
Exoenzyme S (ExoS) and other proteins (ExoT, ExoY, ExoU)
are injected into host cells directly by type III secretion system.
Once inside the host cell, ExoS acts on regulatory G proteins
affecting the cytoskeleton, inducing apoptosis.41, 79
Due to the action of these virulence factors, P. aeruginosa
is able to cause a wide range of urinary, pulmonary or soft
tissue infections. Moreover, once infection is stablished, P. aeruginosa
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is overwhelming virulent and very difficult to treat. In addition,
immunocompromised patients such as CF patients or AIDS patients
are more prone to suffer these infections.
1.4.2 Epidemiology
P. aeruginosa is known as an opportunistic pathogen which
habitat is the environment (water, soil or vegetation). However, 2
to 10% of the humankind are colonized by this bacterium, being
throat and stool the main places of isolation. As said above, P.
aeruginosa rarely infects healthy people but is one of the most
important causes of nosocomial infections in non-healthy people i.e.
CF patients, extensive burns or leukaemia.41
1.4.3 Pathogenesis
P. aeruginosa expresses an abundance of virulence factors but
against expected strains isolated from CF lungs lack some of
them. Firstly P. aeruginosa have to invade and/or penetrate host.80
Flagella and type 4 pili are involved in adherence to epithelial cells
which is the first step to initiate infection. However, the most
studied virulence factors in P. aeruginosa are type 3 secretion system,
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quorum sensing (QS) and lipopolysaccharide (LPS). Briefly, type 3
secretion system injects toxins into host cells and its expression
is related to acute infections.81 QS is a poor-known mechanism
of bacteria that leads an intercommunication between individuals in
order to adapt to environmental changes.82 Finally, LPS is involved
on antigenicity, interaction with antimicrobials and inflammatory
response.80, 83
1.4.4 Adaptation
P. aeruginosa is not static, but it is able to adapt (specially
in lung) in order to escape the antimicrobial treatment. Moreover,
prolonged infections characteristic of CF help to select resistant or
mutant isolates.
Some adaptative traits such as mucoid phenotype, antibiotic
resistance, alterations in lipopolysaccharide (LPS), loss of type III
secretion and motility, auxotrophy, SCVs, defects in quorum sensing
and hypermutability.33
Mucoid phenotype is the most studied P. aeruginosa adaption
in CF patients because it is the most predominant adaption in
these patients. This phenotype is due to an overproduction of the
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exopolysaccharide alginate, this polymer is based on D-manuronic
acid and L-guluronic acid.84 P. aeruginosa has an operon that
contents most of the genes responsible for alginate synthesis.
Upregulation of the operon throw an overproduction of alginate
and the subsequent mucoid phenotype. This overproduction is
beneficial to P. aeruginosa because it prevents bacterial clearance by
both host and antimicrobial therapy growing in biofilm.85 Moreover,
opsonization and phagocytosis are impeded by alginate.86 Finally, it
is suggested that exopolysaccharide has immunomodulatory properties
which would be able to dysregulate immune response.87 In
conclusion, some authors postulate that emergence of the mucoid
phenotype coincides with the transition from the intermittent to
the chronic phase of infection.88, 89
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Antibiotic resistance is another adaptation mechanism which
is very common because of patients (especially CF patients) are
exposed during long time to antimicrobials.90 This exposition
acts as a selective pressure in P. aeruginosa, selecting individuals
that are intrinsically resistant to a given antibiotic. The level of
resistance tends to increase according to the number of antibiotic
courses, therefore is a marker of how the advance the disease is.
Panresistant bacteria has the worst survival outcome.
Modification of LPS. LPS consist of three parts: Lipid
A which is very toxic and highly acylated, a central core
oligosaccharide attached to lipid A and the O antigen which is
nonessential polysaccharide.
O-antigen usually is missing in P. aeruginosa isolates from
CF patients. This absence may contribute to chronic persistence
within the CF patients because of O-antigen is highly immunogenic
provoking a strong antibody response.91 Recently, it has been
demonstrated that lipid A may be altered in P. aeruginosa isolates
from CF patients. These alterations consist in different acylation
patterns.92
Loss of type III secretion. Almost all environmental P.
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aeruginosa are able to secrete toxic proteins (such as ExoS, ExoT,
ExoU, ExoY among others) trough type III secretion, but during
infection only 45% of isolates from newly infected children or 12%
of chronically infected adults are able to secrete these proteins.93–95
This adaptation is due to individuals with CF secreting antibodies
against proteins secreted by type III secretion, therefore a P.
aeruginosa isolates defective in type III secretion are more likely to
survive in CF patient lung.
Loss of motility. P. aeruginosa cultured from CF patients are
usually defective in swimming motility since they are unable to
produce their flagella.96 It has been seen that P. aeruginosa cultured
from early infections patients has their flagella therefore, this loss
of flagella occurs during infection. In addition, P. aeruginosa has
the ability of movement between surfaces through a process called
twitching motility. This movement is mediated by the extension
and retraction of type IV pili32. CF chronic infections is linked
with loss of twitching movement as well.97
Auxotrophy and metabolic adaptations. Frequently, P.
aeruginosa from CF patients growths slowly, this effect suggest the
existence of a defective metabolic pathway such as an auxotrophy.98
The most common auxotrophy involves amino acids methionine,
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leucine and arginine i.e. that auxotroph strains are unable to
synthesize these amino acids in order to synthesize proteins.99
Nevertheless, secretions of CF patients have a high concentration
of amino acids therefore these auxotrophic strains may survive and
expand infection. Some studies thrown that auxotrophic strains are
associated with severe infections.100
Small-colony variants (SCVs). Like S. aureus, P. aeruginosa
is able to form SCVs. They are present in almost 10% of
the respiratory samples of CF patients69 and have some special
characteristics: take more than 48h to appear in culture plates, they
autoaggregate in liquid culture, are hyperadherent to surfaces, have
reduce motility and enhanced antimicrobial resistance.33
These characteristics promote the biofilm mode of growth
in respiratory airways. Their phenotype is correlated with changes
in expression of chemosensory, exopolysaccharide and two-component
system. However, SCVs differs significantly from each other their
gene expression. Therefore, SCVs represent a heterogeneous group
that have in common just their phenotypes.
Defects in quorum sensing (QS). QS is defined as the
mechanism whereby individual bacterium communicates with another
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in order to alter gene expression in response to changes in
population density or external stimuli.101 In order to achieve
these proposals, bacteria secrete molecules called autoinducers which
are detected by other bacteria. The most studied molecules are
3-oxo-dodecanoyl homoserine lactone produced by the LasI/LasR
system and butyryl homoserine lactone produced by RhlI/RhlR
system.102 It has been seen that in vitro QS systems modulate 6
to 10% of the genes in P. aeruginosa genome, determinant virulence
factors are included such as elastase, alkaline protease, phospholipase
C, pyocyanin and exotoxin A, among others.103–105 Due to these
virulence factors regulation, QS plays a key role in pathogenesis of
P. aeruginosa infection. Notwithstanding, many P. aeruginosa isolates
from CF patients fail to produce homoserine lactones.106 This
paradoxical event is explained by the emergence of “social cheaters”,
bacteria that do not respond to autoinducer signals, but they
benefit by autoinducers produced by other bacteria.107 As occurs
with type III secretion, flagella or other virulence systems are
lost once chronic infection is established inasmuch as this energy
expenditure is only affordable to initiate an infection.
Hypermutable phenotype. P. aeruginosa may presents a
hypermutable phenotype as occurs with S. aureus. Briefly, 37 to 54%
isolates from CF patients are hypermutable, while acute infections
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has 1% or environmental isolates are 6%.108, 109 This phenotype
occurs when mutS, mutL and uvrD genes mutate preventing
expression of proof-reading proteins that control correcting errors
in DNA replication.110, 111 Mutation ratio in hypermutable phenotype
is 20- to 1000-fold than normal phenotype; it is believed that
these mutations are responsible for many adaptations such as above
mentioned. Moreover, hypermutable strains are more resistant to
antibiotics, usually are mucoid and defective in QS, and in general
more versatile to adapt in tough environment CF airways.105, 112–114
1.5 Microbial biofilm
The concept of biofilm is controversial and remains unclear.
In 1975, Marshall defined it as “very fine extracellular polymer
fibrils”.115 Later, in 2002, Donlan and Costeron amplified the
definition to “a microbially derived sessile community characterized
by cells that are irreversibly attached to a substratum or interface
or to each other, are embedded in a matrix of extracellular
polymeric substances that they have produced, and exhibit
an altered phenotype with respect to growth rate and gene
transcription”.116 Growth in a biofilm provides bacteria a defence
against several clearance mechanisms.117 Extracellular polymeric
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matrix is one of these protection mechanisms; composition varies
between species and strains but in general contains host factors,
polysaccharides and extracellular DNA (eDNA).118, 119 Contrary to
was expected, biofilms growth stronger and faster in a very rapid
flowing milieus environment. It has been established that bacteria
form stronger biofilm the higher Reynolds number (the higher
Reynolds number, the more turbulent the flow).116
Many infections that affect to human beings are caused by
bacterial biofilms such as endocarditis, otitis media, chronic bacterial
prostatitis, cystic fibrosis, periodontitis; additionally, biofilms have the
ability to colonize abiotic surfaces such as prosthetic heart valves,
central venous catheters, urinary catheters, contact lenses, intrauterine
devices, dental unit water lines, among others116. Biofilm life
cycle has been studied for years and nowadays remains quite
unclear. Briefly, biofilm life cycle consists at least three phases:
attachment to an abiotic or biotic surface, maturation and dispersal.
Some authors add another phase called “microcolony formation” as
intermediate between attachment and maturation. Bacterial adhesins
are responsible to the attachment, whilst maturation is mediated by
cell-cell adhesion. Finally, dispersion is carried out by enzymes that
degrade biofilm matrix.117, 120
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1.5.1 S. aureus biofilm
Depending on the bacterial species, biofilm will be formed
in a different way. Recent studies show that S. aureus biofilm
formation has another more stage; this stage consists in an early
dispersal phase called “exodus”. Exodus leave behind small foci
of biofilm that grows in tower structures.121 Another interesting
point is biofilm matrix, S. aureus biofilm matrix is a cement
that encompasses bacteria, host factors, secreted and lysis-derived
proteins, polysaccharides and eDNA from lysed bacteria and from
host neutrophil cell death. Polysaccharide intercellular adhesin
(PIA) is the component with the largest proportion in S. aureus
biofilm.122 PIA is built with β-1,6-linked N-acetylglucosamine
molecules encoded in the icaADBC locus.117 Structural integrity
of biofilm both in vivo and in vitro are rule by PIA polymers,
notwithstanding some reports have shown that some S. aureus
strains are able to growth in biofilm while lacking ica locus.123
These PIA-deficient biofilms have a matrix rich in eDNA and
proteins that play the role of adhesins in the absence of PIA.124
Proteins such as protein A, fibrinogen-biding proteins (FnBPA and
FnBPB), biofilm-associated protein (Bap), clumping factor B (ClfB)
or S. aureus surface protein (SasG) are involved in the attachment
and biofilm matrix development.125, 126 Moreover, biofilm maturation
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Figure 1.5: S. aureus biofilm formation phases120
is regulated by extracellular adherence protein (Eap) and beta toxin
(HlB).127 Recently, eDNA is one of the latest identified in biofilm
matrix which acts as an electrostatic polymer that anchors biofilm
to surfaces. Because of this presence of eDNA, non-mature biofilms
are more sensitive to DNases having a key role during attachment
to surfaces.128 Some studies thrown that this eDNA is produced
by autolysis of a subpopulation of the bacteria.129 It is presumed
that this altruistic suicide is important in the biofilm dispersal
mechanisms117. Additionally, adhesins and a number of cytoplasmic
proteins are found in biofilm matrix as well.130 Interestingly,
although teichoic acids have been also found in biofilm matrix,
their role in virulence and infection remain not fully stablished.131–133
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Nowadays, dispersal strategies developed by S. aureus are the
subject of many studies. Briefly, S. aureus uses various exo-enzymes
such as DNases and surfactants to degrade the extracellular
polymeric matrix.134 Its accessory gene regulatory (agr) system is the
responsible to control the production of these degrading enzymes.
For instance, an hypothetical inhibition of genes encoding these
proteases (agr) results in a significant increase in biofilm formation
and in an almost inexistent disassembly.135 Another DNase known
as thermonuclease has been also involved in cell detachment from
biofilm as well.128
Enzymatic dispersal mechanisms developed by S. aureus involve
protease-mediated dispersal, nuclease-mediated, dispersin B-mediated,
among others.117
1.5.2 P. aeruginosa biofilm
Two stages are differentiated in the formation of P.
aeruginosa biofilm. First stage occurs in a reversible way, in the
case of CF, planktonic P. aeruginosa cells adhere to the gel phase
of airway lining fluid. Flagella and pili are critical in this stage.
Second stage is irreversible, bacterial cells begin to divide and form
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clusters giving rise to an early biofilm. In this step intervenes
type 4 pili and lasIR which produces a signal molecule called
3-oxododecanoyl-homoserine lactone.136 Moreover, alginate is produced
due to mutations in mucA. This mutation occurs because of the
presence of oxygen free radicals that activates polymorphonuclear
leukocytes (PMN) in the inflammatory reaction. Finally, autolysis
of PMN entails releasing of DNA facilitating biofilm formation as
occurs in Gram-positive bacteria.137
As it happens with S. aureus, a huge number of factors
are involved in the formation of P. aeruginosa biofilm. One of
the main factors is quorum-sensing systems; P. aeruginosa has two
of them that are key processes in biofilm development, las and
rhl.138, 139 For instance, maturation biofilm entails the formation of
tower-like structures within water channels that allow exchange of
nutrients and is led by rhlR which produce the signal molecule
called N-butanoyl-homoserine lactone.
In the deeper layers of biofilm, it can be found
metabolically inactive bacteria involved in high resistance to
antibiotics. Finally, biofilm lifecycle is completed with the dispersion
of planktonic bacteria from the outermost layers of biofilm.140
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1.6 Antimicrobial treatment and resistance
mechanisms
In the context of CF both S. aureus and P. aeruginosa
are major concern in antimicrobial therapy. Since these two
microorganisms are morphologically and physiologically different,
different family of antimicrobials are used.
1.6.1 S. aureus
The prevalence of MRSA in the respiratory tract of CF
patients is increasing year by year, becoming the main concern in
S. aureus antibiotic therapy.
Vancomycin is one of the first elections to treat MRSA in
CF paediatric population. Nevertheless, vancomycin has a limited
penetration into the lung and biofilm formed by S. aureus. Another
first-line antibiotic to treat S. aureus is linezolid. In opposition
to vancomycin, linezolid has a good oral bioavailability.141 Some
cases of resistance to linezolid have been reported , but nowadays
resistance remains at very low percentages.142
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Tetracyclines are in a second antibiotic election. Historically,
tetracyclines such as doxycycline are known as effective against
MRSA. Resistance to tetracyclines is relatively low but increasing
year by year.143
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Trimethoprim/Sulfamethoxazole (TMP/SMX) is an oral
and intravenous antibiotic with broad-spectrum action, but
this combination has a worthy lung penetration. It has been
reported many resistance rates but in CF population remain low.
TMP/SMX has demonstrated a huge activity against S. aureus
SCVs.144
Other antibiotics used to treat S. aureus in CF population
are ceftaroline, ceftobiprole, clindamycin, telavancin or tigecycline.
Ceftaroline and ceftobiprole are cephalosporins that have a
promising potential due to their unique antibacterial spectrum
and good tolerability. They are used against MRSA, VISA,
linezolid-resistant S. aureus and even against Gram-negative bacteria
such as P. aeruginosa. On the other hand, clindamycin use is
limited by its high rates of resistance. Telavancin is derivate
from vancomycin with a narrow-spectrum against Gram-positive
bacteria, including MRSA, hVISA and VRSA. Its use is limited
because of a higher frequency of nephrotoxicity, especially in CF
patients due to these patients probably are medicated with another
nephrotoxicity antibiotic such as colistin. Finally, tigecycline has
a broad-spectrum activity and an extensive tissue distribution. In
addition, lung penetration is good and resistance rates remains low
in MRSA isolates form CF patients. Unfortunately, tigecycline
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has demonstrated a limited action against S. aureus in CF
patients.141 Although daptomycin is not recommended use for
lung MRSA because is inactivated by surfactant,145 it is very active
in combination with other antibiotics such as β-lactams, ceftaroline,
TMP/SMX, rifampin, or Fosfomycin.146
1.6.2 S. aureus antimicrobial resistance mechanisms
S. aureus resistance comes mainly from horizontal DNA
transfer of another microorganisms. These mechanisms have the
advantage of gaining a pre-assembled packet encoding resistance to
multiple antibiotics147. Resistance to β-lactam is produced by an
enzyme called penicillinase which hydrolyses ring penicillin amide
bond. Practically all S. aureus strains have acquired resistance to
penicillin family in the first decades of its clinical use. Penicillinase
production is regulated by blaZ gene, which in turn is under the
control of blaI and blaR1 genes. Usually, these genes are carried
in plasmids together with other genes that provides resistance to
another antibiotics, giving them a large dispersion.147
Methicillin resistance is one of the most relevant resistance
in S. aureus. Due to this characteristic, S. aureus is divided into
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Table 1.1: S. aureus antimicrobial treatment
ANTIBIOTIC FAMILY MoA MoR
Vancomycin Glucopeptide Inhibition cell wallsynthesis
Alteration
NAM/NAG
subunits
Linezolid Oxazolidinone Protein synthesisinhibitor
Efflux pumps
Mutation genes
encoded 23s
ribosomal RNA
Daptomycin Lipopetide Disrupts bacterialcell membrane
Cell
membrane/wall
perturbations
TMP/SMX DFRInh+Sulfonamide
Inhibits folate
synthesis
Stop folate
pathway
Doxycycline Tetracycline Inhibits proteinsynthesis
Efflux pump
Ribosomal
protection protein
Clindamycin Lincosamide Inhibits ribosomaltranslocation
adenine
methylation in 23S
subunit
Telavancin Lipoglicopeptide Inhibits cell wallsynthesis -
Tygecicline Glycylcycline Proteins synthesisinhibitor
Efflux pump
Mutations in
ribosomal genes
Ceftaroline Cephalosporin
Binds to
penicillin-binding
proteins (PBPs)
-
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MRSA or MSSA. MRSA distinction implies resistance to β-lactam
antibiotics including cephalosporins and carbapenems. Frequently,
MRSA is usually resistant to other antibiotics such as tobramycin
or erythromycin, among others. S. aureus mechanism of resistance
to methicillin is the production of an additional penicillin-binding
protein (PBP2a) with reduced affinity for penicillins.147 Genes
involved are mecA, mecI and mecR1 which have similarities with
bla genes family.
Vancomycin resistant was practically inexistent until late
nineties. Lately, it has been reported an increasing number
of Vancomycin-resistant (VRSA) isolates as well as Vancomycin
intermediate-resistant (VISA) S. aureus. First VISA was found in
Japan in 1997148 and first isolate of VRSA was found in United
States in 2002.149 VISA phenotype is the result of a failure in
the treatment of nosocomial infections, nowadays viable alternatives
to VISA treatment are combination of high-dose daptomycin with
another antibiotic such as gentamicin, rifampicin or linezolid.150 It
is being believed that VISA apparition is due to the existence of a
heterogeneous VISA culture (hVISA). This culture has a very low
number of colonies (10−6 to 10−5) VISA and when the treatment
with vancomycin starts only these isolates survive resulting in a
fully VISA culture.151
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Resistance is mediated by the vanA operon, probably
transferred from Enterococcus faecalis on the plasmid-borne transposon
Tn1546.152 VanA encodes a modified synthesis of peptidoglycan
containing D-Ala-D-Dlac instead of D-Ala-D-Ala. Nowadays, VRSA
has remained extremely rare, but the number of these isolates is
increasing.
Although linezolid remains highly active against S. aureus,
resistance was firstly described in a patient with a MRSA
peritonitis in 2001.153 It occurs when there are mutations in
the linezolid 23S rRNA binding site ([G2576T]), other ribosomal
mutation described is [T2500A] in ribosomal proteins of the
peptide translocation centre or by plasmid-borne acquisition with
methyltransferase gene (cfr).154
Daptomycin has a unique mechanism of action consisting
in binding and as further insertion into bacterial cytoplasmic
membrane in the presence of calcium ions.147 Due to this
uncommon mechanism of action, resistance has no developed
swiftly. However, it has been reported some protein mutations
involve daptomycin resistance, although the main cause of resistance
is due to perturbations in the cell membrane and even in the
cell wall of bacteria.155 Recently, some cross-resistance with VISA
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has been reported. Some authors attribute this phenomenon to a
thickened cell wall typical of VISA that would prevent daptomycin
penetration.156
Figure 1.6: Targets of antimicrobials in S. aureus54
TMP/SMX is usually chosen as treatment in severe lung
infections due to its appropriate lung penetration. Nevertheless,
several resistances due to the interruption of folate pathway in an
easy manner have been reported. Moreover, TMP/SMX selects S.
aureus SCVs, associated with worse lung prognosis.141, 143
On the other hand, tetracycline resistance is due to two
different mechanisms; ribosome protection encoded by tet(M) and
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tet(O) genes and drug efflux by tet(K) and tet(L) genes carried
on plasmids.157 Resistance to clindamycin is rising year by year.
Briefly, resistance is due to a family of genes called erm, encoding
adenine methylation in 23S subunit.158 Telavancin resistance involve
up-mentioned genes plasmid-mediated vanA.159 Bacterial tigecycline
resistance involve mutations in efflux pumps.160
1.6.3 P. aeruginosa
Nowadays, antibiotic therapy against P. aeruginosa is focusing
in reduce bacterial mass in lung in a fastest manner in order
to avoid selection of mutants and prevent phenotypic tolerance.
Bacterial drugs such as β-lactams or aminoglycosides are the best
choice to face P. aeruginosa infections.
Cephalosporins are one of the most studied family of
antibiotics. Their mechanism of action consist on the inhibition
of the third step of the synthesis of bacterial cell wall by
binding to penicillin-binding proteins (PBPs).161 Carbapenems,
specially meropenem and imipenem, are β-lactam a broad-spectrum
antimicrobials used for treatment of multidrug-resistant P. aeruginosa
(MDRPA). The use of imipenem is in principle reserved to
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severe infections where microorganisms have acquired resistance
to up-mentioned drugs. Monobactam is a subfamily of β-lactam
antibiotics. The best known molecule is aztreonam, which binds
to the PBP3 disrupting bacteria.162
Fluoroquinolones have a slower bacterial activity proportional
to the dose but, contrary to expected higher doses are less efficient.
Fluoroquinolones, such as ciprofloxacin, levofloxacin, norfloxacin,
among others, target type II topoisomerases DNA gyrase (which
are encoded by rA and rB) and topoisomerase IV as well.
The duty of these enzymes consists on modulate DNA supercoiling
replication. Fluoroquinolones prevent this modulate provoking cell
death.163 Aminoglycosides, such as amikacin or tobramycin, are
another family chosen in order to facing P. aeruginosa infections.
Their mechanism of action dwells on block the synthesis of
ribosome proteins preventing codon-anticodon matching.164
The emergence of MDRPA, as well as, the lack of new
drugs to combat them, has stimulated the rescue of polymyxins as
a therapeutic option. Polymyxins are known since 1949 but they
were left largely unused in seventies because of their nephrotoxicity
and neurotoxicity and the availability of less toxic drugs which
bacteria had not yet developed resistance. Colistin is the most
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known polymyxin; its amphipathic character is relevant to its
activity against bacteria. Hydrophilic part, positively charged, would
interact with the negatively-charged bacterial outer membrane. On
the other hand, hydrophobic part would be allowed entry through
the bacterial cytoplasmic membrane.
Figure 1.7: Polymyxin B molecule
This mechanism remains quite unclear, some authors propose
that divalent cations such as Mg2+ and Ca2+ have an important
role in the interaction with binding sites between colistin and
outer membrane, among others.165 Competitive binding resulting
would disturb the properties and stability of outer membrane.
Ultimately, death would be due to peptide insertion into the
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cytoplasmic membrane, forming channels where small molecules,
ions and even proteins would pass.161
Table 1.2: P. aeruginosa antimicrobial treatment
ANTIBIOTIC FAMILY MoA MoR
Cephalosporin β-lactam Bind to PBPs β-lactamases andEfflux pumps
Tobramycin
Amikacin Aminoglycoside
Block the synthesis
of ribosome
proteins
AMEs and rRNA
methylases Efflux
pumps
Ciprofloxacin Fluoroquinolone DNA gyrase andTopoisomerase IV
DNA gyrase and
Topoisomerase IV
mutations and
Efflux pumps
Imipenem
Meropenem Carbapenem Bind to PBPs
β-lactameses,
Efflux pumps and
Loss OprD
Aztreonam Monobactam Bind to PBPs β-lactamases andEfflux pumps
Colistin Polymyxin Disrupt outermembrane
Modification Lipid
A
1.6.4 P. aeruginosa antimicrobial resistance mechanisms
Resistance to β-lactams (penicillins, cephalosporins,
carbapenems and monobactams) is increasing year by year. P.
aeruginosa has a quite variety of mechanisms to avoid bactericidal
effect: β-lactamases, carbapenemases efflux pumps and permeability.
In the context of β-lactamases, four molecular families have been
described (A-D), class B is a metal dependent enzyme (Zn2+) and
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A, C and D are metal independent enzymes.166, 167
Within β-lactamases it can be differentiate between
endogenous or acquired. Mostly P. aeruginosa strains have two
intrinsic β-lactamases, AmpC (giving resistance to cephalosporines)
and PoxB (giving resistance to oxacillinase).168 Acquired β-lactamases
usually are encoded by plasmids and they can hydrolyse a wider
range of β-lactams; for instance, extended-spectrum β-lactamase
(ESBL) are able to hydrolyse cephalosporins and monobactams.169
In addition, other family of β-lactamases called carbapenemases
leading to hydrolyze carbapenems. There are several families
of carbapenemases such as GES, IMI, KPC, NMC-A and
SME. One of the most important is KPC which is able to
hydrolyse oxy-iminocephalosporins, monobactams and carbapenems.170
Unfortunately, imipenem resistant isolates have emerged in last
years.161 Principally, mechanism of resistance to carbapenem in P.
aeruginosa consists of the loss or the inactivation of OprD porin,
this porin facilitates amino acids diffusion and allows carbapenems
penetrance.171
Resistance to aminoglycosides occurs principally by
aminoglycoside-modifying enzymes (AMEs) and rRNA methylases.
These enzymes have been classified depending on molecular
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target. Briefly, aminoglycoside acetyltransferase modifies 3
[3-N-aminoglycoside acetyltransferase] and 6’ [ 6’-N-aminoglycoside
acetyltransferases] (AAC family give resistance to gentamicin,
tobramycin, netilmicin, amikacin, among others166. Aminoglycoside
nucleotidyltransferases (ANT) inactivate gentamicin, tobramycin,
amikacin. Finally, aminoglycoside phosphoryltransferases (APH) give
resistance to kanamycin, neomycin and streptomycin.172
Lately, other mechanism involving 16S rRNA methylation
which interferes in the aminoglycoside binding site giving resistance
to gentamicin, tobramycin and amikacin have been described.173
Resistance to fluoroquinolones is mainly mediated by DNA
gyrase and topoisomerase IV mutations.174 Quinolone resistance
determining region (QRDR) is the region where mutations occur
with more percentage. This region encompasses GyrA of DNA
gyrase and ParC of topoisomerase.175
All these antibiotic families (β-lactams, fluoroquinolones,
aminoglycosides) are susceptible to be expelled by efflux pumps.
P. aeruginosa has a wide variety of efflux pump systems. Shortly,
resistance to β-lactams is provided by MexAB-OprM, MexCD-OprJ
or MexXY-OprM systems. MexAB-OprM, MexCD-OprJ,
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MexEF-oprN and MexXY-OprM provide resistance to fluoroquinoles.
And finally MexXY-OprM gives resistance to aminoglycosides.166
Nowadays, it has been reported some resistances to
polymyxins (polymyxin B and colistin) or other polycations.
Resistance mechanism(s) remains quite unclear, but it is believed
that a reduced negative charge on the bacterial outer membrane
leading a lipid A modification is key in developed the resistance.161
1.7 Discovery of new compounds
The discovery of new compounds with antimicrobial capacity
is expensive (hundreds of millions of euros) and long process (12-15
years). Moreover, there are hard regulatory laws that complicate
even more the success. There are not too many strategies in order
to develop these possible antimicrobial compounds; they consist
on seeking new molecules in nature, laboratory synthesis, in silico
studies and modifications of known molecules.
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1.7.1 Natural compounds and synthesis
Historically, most of antibiotics used in clinics are natural
compounds from environment whether from plants, animals or
other microorganisms.176 Nowadays, there are an overwhelming
number of publications seeking for new molecules in nature with
antimicrobial capacity and low toxicity. One of the main handicaps
lies isolating these molecules from natural extracts. For this reason,
laboratory synthesis mimicking natural molecules is envisaged as a
promising strategy.
In conclusion, these two methods are the most extended to
develop new antimicrobial molecules.
1.7.2 In silico
In silico is a contemporaneous term that refers
experimentation performed by computer. Briefly, software is used in
order to analyse and integrate biological and medical data creating
models that simulate and predict hypotheses results. One of the
most important kind of in silico experiments is to predict possible
interactions between studied molecule and its target with the final
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purpose determine an eventual antimicrobial capacity.177
1.7.3 “Old compounds” modifications
One of the strategies which nowadays are most studied is
scaffold modifications of known drugs. As mentioned in previous
sections, polymyxins were abandoned due to toxicity concerns
in seventies but nowadays is one of the last-line antibiotics to
tackle multidrug-resistant bacteria. In parallel, there are several
both academic and industrial groups working on reducing toxicity
and improving antimicrobial capacity of polymyxin-based new
molecules161, 178, 179or even granting new therapeutic possibilities
extending its spectrum of action180For all of this, we have focused
on synthesizing and exploring polymyxin-based peptides against
multidrug resistant bacteria.
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2 . HYPOTHESIS AND OBJECTIVES

Objectives
2.1 Hypothesis
The Synthetic Peptides based on Polymyxin structure may
constitute a therapeutic option in infections caused by Multidrug
Resistant Bacteria.
2.2 Justification of the study and objectives
Multidrug-resistant bacteria is one of the major concerns
in public health. Nowadays, the number of isolates resistant to
almost all known antibiotics has increased in an overwhelming
way. It is worrisome in the context of cystic fibrosis; colistin
has been rescued, despite of its toxicity, in order to treat
strains which have developed resistance to antimicrobials frequently
used against this disease such as carbapenems or aminoglycosides.
Unfortunately, colistin-resistant strains are increasing as well year
by year. The goal standard of our studies was the synthesis,
antimicrobial determination and exploration of mechanisms of action
of new compounds mimicking colistin scaffold with some chemical
modifications as a new therapeutic option to multidrug-resistant
bacteria specially in the context of cystic fibrosis.
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Main objectives:
1. Synthesis and characterization of polymyxin-based peptides
(a) Peptide synthesis following standard Fmoc/tBu methods
(b) Purification and characterization of the peptides
2. Antimicrobial activity of peptides against MDR clinical isolates
(a) Determination of the antimicrobial effect on planktonic
bacteria
(b) Determination of the synergistic antimicrobial effect on
planktonic cultures with commercial antibiotics
(c) Determination of the antimicrobial effect on biofilm
formation
(d) Determination of the synergistic antimicrobial effect on
biofilm formation with commercial antibiotics
3. Study of the toxicity of the peptides
4. Exploration of the mechanisms of action of the peptides
(a) Study outer membrane disruption using Transmission
Electronic Microscopy
(b) Study peptide interaction with teichoic acids from S.
aureus
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Abstract: The aim was to explore the antimicrobial activity of a synthetic peptide (AMP38)
and its synergy with imipenem against imipenem-resistant Pseudomonas aeruginosa. The main
mechanism of imipenem resistance is the loss or alteration of protein OprD. Time-kill and minimal
biofilm eradication concentration (MBEC) determinations were carried out by using clinical
imipenem-resistant strains. AMP38 was markedly synergistic with imipenem when determined in
imipenem-resistant P. aeruginosa. MBEC obtained for the combination of AMP38 and imipenem was
of 62.5 µg/mL, whereas the MBEC of each antimicrobial separately was 500 µg/mL. AMP38 should
be regarded as a promising antimicrobial to fight MDR P. aeruginosa infections. Moreover, killing
effect and antibiofilm activity of AMP38 plus imipenem was much higher than that of colistin
plus imipenem.
Keywords: Pseudomonas; antimicrobial peptides; synergism; biofilm eradication
1. Introduction
Pseudomonas aeruginosa is a nosocomial opportunistic pathogen causing a wide variety of
both acute and chronic infections, such as pneumonia, bacteraemia, and urinary tract infections.
Immunocompromised patients and those suffering cystic fibrosis show a particularly high susceptibility
to infection by this microorganism [1].
Moreover, the increasing frequency of the isolation of multidrug-resistant Pseudomonas aeruginosa
(MDRPA) is a major cause for concern. Antimicrobial resistance in P. aeruginosa is caused by three
well-known basic mechanisms: uptake and efflux balance, target modifications, and inactivation of the
drug [2,3].
Carbapenems—particularly imipenem—are broad-spectrum antimicrobials commonly used for
the treatment of MDRPA infections. Their mechanism of action is based in the inhibition of the third
step of the synthesis of bacterial cell wall by binding to certain penicillin-binding proteins (PBPs).
Imipenem is active against a wide variety of microorganisms, both Gram-negative (P. aeruginosa,
Acinetobacter spp.) and Gram-positive (Streptococcus pneumoniae and Enterococcus faecalis) [4,5]. The use
of this antimicrobial is in principle restricted to severe infections where microorganisms have acquired
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resistance to other drugs. Unfortunately, imipenem-resistant isolates have emerged in the last few
years. The main mechanisms of resistance to carbapenems in P. aeruginosa are the loss or the alteration
of the OprD porin, an outer membrane protein that facilitates the diffusion of basic amino acids and
allows penetration of carbapenems (and particularly imipenem) into the bacterium, the production
of β-lactamases, and the overexpression of efflux pumps [6,7]. The loss of porin OprD and the
overproduction of extended-spectrum cephalosporinases (ESACs) that weakly hydrolyze carbapenems
has been observed in 100% and 92% of the meropenem-resistant isolates, respectively. P. aeruginosa
can very often accumulate different resistance mechanisms, including ESAC production, leading to
carbapenem resistance [8]. The emergence of multidrug-resistant Gram-negative bacteria, as well as
the lack of new drugs to combat them, has stimulated the rescue of polymyxins as therapeutic options.
Polymyxins are cyclic peptides with antimicrobial action that have been available since 1949, although
they were left largely unused during the seventies because of their nephrotoxicity and the availability
of less toxic antimicrobials to which bacteria had not yet developed resistance [9].
The most known polymyxin is colistin; like other cationic polypeptides, colistin is an amphipathic
compound. It is believed that this amphipathic nature is relevant to its activity against bacteria.
The hydrophilic part (positively charged) would interact with the negatively-charged bacterial outer
membrane. In this way, the hydrophobic part of the polypeptide would be allowed entry through
the bacterial cytoplasmic membrane. Another mechanism proposed is the interaction with binding
sites of divalent cations such as Mg2+ and Ca2+; this competitive binding would disturb the properties
and stability of the outer membrane. Ultimately, bacterial death would be due to the insertion of the
peptide into the cytoplasmic membrane, forming channels where small molecules, ions, and even
proteins would pass—and that could also eventually be used as a way for other antimicrobial agents
to penetrate the bacteria [10,11].
The exploration of antimicrobial peptides (AMP) mimicking the structure and mechanism of
action of polymyxins can be regarded as a main goal of this field of research. Such synthetic AMPs
would allow opening perspectives in order to reduce secondary effects and enhance antimicrobial
action. Moreover, there are several experimental and clinical studies regarding the synergistic activity
of colistin with other antimicrobial agents against MDRPA (azlocillin, aztreonam, ceftazidime, or
ciprofloxacin, among others) [12–14]. Carbapenems are the most commonly used antibiotics to
test these eventual synergies, although there is a huge heterogeneity in the published results [15].
The efficacy of colistin in monotherapy against beta-lactam-susceptible bacteria is lower than that of
β-lactams, but when used combined with other antimicrobials, they reach higher effectiveness [16].
The increase in the use of polymyxins has resulted in the emergence of worldwide
polymyxin-resistant P. aeruginosa isolates. This resistance lies behind a reduced negative charge
on the bacterial outer membrane which has been shown to be a specific modification of lipid A
in the LPS [17]. The synthesis of safe and effective antimicrobial peptides in the laboratory could
open new frontiers to combating multidrug resistance—an unlimited number of new molecules with
antimicrobial activity could be designed. The challenge lies in finding new molecules with higher
activity and lower toxicity than conventional known drugs.
The aim of this study was to explore the antimicrobial activity of a novel synthetic cyclolipopeptide
analog of polymyxin (AMP38) and its synergy with carbapenems in order to contribute to the
improvement of treatments for infections caused by carbapenem-resistant P. aeruginosa. AMP38 was
previously described as one of the most effective peptides of a series synthesized by Rabanal et al. [18].
2. Results
Clinically used polymyxins are cyclic lipopeptides with a tail-to-side-chain amide bond (Figure 1).
The fatty acid tail typically contains a stereocenter. Although their synthesis is accessible using
chemical methods, a first goal was to reduce the complexity of the macrocyclic backbone scaffold
to facilitate the generation of analogues and future preparation at high scale. A plausible approach
would consist of substituting the amide bond by an isosteric and more chemically-accessible link,
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such as a disulfide bond. Disulfides are also chemical linkages present in some cyclic peptide
drugs, as discussed below. Loop structures linked by disulfide bonds are not uncommon in
cyclic AMPs. Examples are found in bactenicin (from cattle), lactoferricin, brevinins (from frog).
The similarity between the macrocyclic heptapeptide structure in ranalexin and polymyxin was
reported by Zasloff [19]. Similarly, Porro et al. [20] described all-L-amino acid polymyxin-derived
cyclic heptapeptides capable of binding to lipid A having the capability to detoxify bacterial endotoxin
(LPS) in vitro, but lacking antimicrobial activity. Altogether, this background and these structural data
supported the theoretical feasibility of substituting the tail-to-side-chain amide bond with a disulfide
bond. This modification would imply changing both Thr10 and Dab4 for cysteines. In addition, the
C-terminal cysteine would need to be derivatized as a carboxamide to mimic the neutral hydroxyethyl
threonine moiety being substituted, as shown in Figure 1. Furthermore, Cys10 was introduced with
the opposite configuration (D-Cys) to maintain the relative orientation of the moiety.
We also observed in a previous structure–activity study that a norleucine amino acid in position
seven yielded more active analogues than the natural leucine in polymyxin. Finally, the branched
natural fatty acid tail of polymyxin was substituted by a linear tail.
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Figure 1. Chemical structure of the cyclolipopeptide analogue of polymyxin AMP38 (below) and of
natural polymyxin B (above). The structural and chemical features modified in the analogue with
respect to polymyxin are highlighted in blue.
The minimum inhibitory concentration (MIC) values of several antimicrobials against control and
clinical strains are given in Table 1. All clinical isolates were imipenem resistant, and some of them
also presented resistance to tobramycin, aztreonam, amikacin, ciprofloxacin, and meropenem.
Table 1. Antimicrobial susceptibility (minimum inhibitory concentration, MIC) (µg/mL). R: resistant;
S: susceptible.
Antimicrobial Agent ATCC PA116136 023VH 481SJD 536SJD 846VH
IMIPENEM 4 (S) 16 (R) 16 (R) 32/16 (R) 16 (R) >32 (R)
COLISTIN 2 (S) 1 (S) 1/2 (S) 1/2 (S) 1/2 (S) 4 (S)
AMP38 4 32 4/2 16 8/16 0.5/1
TOBRAMICIN 1 (S) 1 (S) 16 (R) 2 (S) 2 (S) 2 (S)
AZTREONAM 8 (S) 2 (S) 2 (S) >32 (R) >32 (R) 16 (S)
AMIKACIN 0.5 (S) 1 (S) >32 (R) 4 (S) 2/ (S) 32 (R)
CIPROFL XACIN 0.5 (S) 0.25 (S) 0.5 (S) 2/4 (R) 4 (R) 16 (R)
MEROPENEM 0.5 (S) 4 (I) 4 (I) 2 (S) 4/8 (I) 32 (R)
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Complementary studies, such as time-kill kinetics or effect on the growth curve have to be
performed to accurately evaluate antimicrobial combinations, mostly to investigate the events
occurring during the period of first hours. As seen in Figure 2A, combinations of sublethal
concentrations of colistin with 4 µg/mL of imipenem did not increase bacterial death. However, when
the concentration of colistin was raised to 4 µg/mL and combined with 0.5 or 4 µg/mL of imipenem,
bacterial death was markedly enhanced and similar for both imipenem concentrations.
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Figure 2. Antibacterial activity of colistin sulphate (COL), imipenem (IMI), meropenem (MER) and
AMP38 in different combinations. (A) ATCC strain; Control (filled circles), IMI 4 µg/mL (open circles),
COL 0.5 µg/mL and IMI 4 µg/mL (filled triangles), COL 4 µg/mL (open triangles), COL 4 µg/mL
and IMI 0.5 µg/mL (filled squares), COL 4 µg/mL and IMI 4 µg/mL (open squares); (B) PA116136
strain; Control (filled circles), COL 0.25 µg/mL and IMI 32 µg/mL (open circles), COL 2 µg/mL
and IMI 4 µg/mL (filled triangles), COL 2 µg/mL and IMI 32 µg/mL (open triangles); (C) PA116136
strain; Control (filled circles), IMI 4 µg/mL (open circles), AMP38 8 µg/mL (filled tria gles), AMP38
8 µg/mL and IMI 4 µg/ L (open triangles); (D) PA116136 strain; Control (filled circles), MER 1 µg/mL
(open circles), AMP38 8 µg/mL (filled triangles), AMP38 8 µg/mL and MER 1 µg/mL (open triangles);
(E) 536SJD strain; Control (filled circles), IMI 4 µg/mL (open circles), AMP38 2 µg/mL (filled triangles),
IMI 4 µg/mL and AMP38 2 µg/mL (open triangles); (F) 481SJD strain; Control (filled circles), IMI
4 µg/mL (open circles), AMP38 4 µg/mL (filled triangles), IMI 4 µg/mL and AMP38 4 µg/mL
(open triangles).
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When determining the killing effect on strain PA116136, we found that colistin at 0.25 µg/mL had
no effect, but when combined with 4 µg/mL imipenem, a synergistic effect was observed (data not
shown). Moreover, higher colistin concentrations (2 µg/mL) exerted a clear concentration-dependent
synergistic effect with imipenem, as can be seen in Figure 2B (with 4 and 32 µg/mL imipenem).
Time kill-kinetics with sub-lethal amounts of imipenem and AMP38 are shown in Figure 2C.
Assays performed with meropenem are summarized in Figure 2D. Other imipenem-resistant isolates
were studied at sublethal concentrations of both AMP38 and imipenem, and with combinations of
both (Figure 2E,F). Similar results to those seen in PA116136 were obtained.
Moreover, the combination of both drugs was also assayed for their effect on the growth curve.
Figure 3 shows one example where a full inhibition of growth occurred when AMP38 and imipenem
were combined at 4 µg/mL of each.
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To quantitatively determine the interaction between APMP38 and imipenem, FIC
(fractional inhibitory concentration) values were calculated. This index is calculated according to
the following formula: FIC of drug A (FIC A) = (MIC of drug A in combination)/(MIC of A); FIC of
drug B (FIC B) = (MIC of drug B in combination)/(MIC of B). The FIC index (FICi) is calculated by
adding FIC A and FIC B. Table 2 shows FICi values of different bacterial strains when tested with
combinations of AMP38 and imipenem.
Table 2. Fractional inhibitory concentration index (FICi) values of imipenem and AMP38 combination.
STRAINS FICi
ATCC 0.62
PA116136 0.14
023VH 0.18
481SJD 0.12
536SJD 0.07
A biofilm of PA116136 was eradicated by the addition of 62.5 µg/mL of both imipenem and
AMP38, whereas imipenem alone failed in eradicating the biofilm at concentrations below 500 µg/mL,
and AMP38’s minimal biofilm eradication concentration (MBEC) was higher than 500 µg/mL (Table 3).
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Table 3. Minimal biofilm eradication concentration (MBEC) of imipenem, AMP38, and the combination
of both antimicrobials (µg/mL).
Antimicrobial Agent PA116136
IMIPENEM >500
AMP38 500
IMIPENEM + AMP38 62.5
TEM observations of ultrathin sections of both P. aeruginosa and Serratia marcescens are shown in
Figure 4. The effect on the bacterial envelopes is in S. marcescens is at least apparently identical to the
one produced by colistin (formation of blebs), whereas in P. aeruginosa, injuries had a different aspect,
lacking blebs and appearing as a rough surface.
Acute toxicity was assessed by an in vivo acute toxicity test on CD-1 mice. The lethal dose (LD50)
was determined according to the up-and-down procedure. Compound AMP38 was administered
subcutaneously at designated doses (100, 200, and 400 mg/kg). Mice treated with 100 and 200 mg/kg
of compound survived with no signs of toxicity; whereas mice administered 400 mg/kg died.
After 14 days, necropsy of the surviving mice (dosed at 200 mg/kg) showed no signs of pathology
in vital organs. LD50 was determined using the maximum likelihood method, and a value of
283 mg/kg was obtained. This value is significantly higher (almost five times) than the LD50
reported for subcutaneous administration of colistin (59.5 mg/kg). Moreover, preliminary cytotoxicity
determination in L-929 and HepG2 cells showed no differences between controls and peptide wells up
to 100 µg/mL (data not shown).
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was 0.625—a value identical to the one determined with colistin and imipenem. This suggests that 
both imipenem and colistin act in a similar manner on this imipenem-susceptible strain. It should be 
noted that, in principle, the entry of imipenem in fully susceptible bacteria is not prevented by the 
outer membrane, since OprD is functional and can allow the penetration of imipenem to the 
periplasmic space, and subsequently, the antibiotic can reach its target. On the contrary, when acting 
on imipenem-resistant strains, the combination of imipenem and AMP38 gave FICi values below 0.5; 
this value has to be considered as strongly synergistic (Table 2). PA116136 is imipenem-resistant, 
since the OprD gene is knocked out by the presence of an insertion sequence [21]; the rest of the 
resistant strains are OprD defective. Subsequently, the entry of imipenem is strongly limited in 
standard culture conditions, and this is the main (if not unique) reason why these bacteria are 
resistant to imipenem. Thus, the synergism between the peptide and the carbapenem should be 
interpreted as a consequence of the ability of peptides to open ways by which imipenem can reach 
Figure 4. TEM electromicrographs of P. aeruginosa PA116136 (a) untreated and (b) AMP38-treated;
and Serratia marcescens NIMA strain (c) untreated and (d) AMP38-treated.
3. Discussion
Colistin has been reported as synergistic with carbapenems and other antimicrobials in
Acinetobacter baumanii, as well as in Pseudomonas and a few other Gram-negative bacteria [15].
Combinations of colistin and imipenem gave a FICi of 0.625 for ATCC 27853; such a value has
to be considered as indifferent. Moreover, when assays were performed with AMP38, the FICi value
was 0.625—a value identical to the one determined with colistin and imipenem. This suggests that
both imipenem and colistin act in a similar manner on this imipenem-susceptible strain. It should
be noted that, in principle, the entry of imipenem in fully susceptible bacteria is not prevented by
the outer membrane, since OprD is functional and can allow the penetration of imipenem to the
periplasmic space, and subsequently, the antibiotic can reach its target. On the contrary, when acting
on imipenem-resistant strains, the combination of imipenem and AMP38 gave FICi values below 0.5;
this value has to be considered as strongly synergistic (Table 2). PA116136 is imipenem-resistant, since
the OprD gene is knocked out by the presence of an insertion sequence [21]; the rest of the resistant
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strains are OprD defective. Subsequently, the entry of imipenem is strongly limited in standard culture
conditions, and this is the main (if not unique) reason why these bacteria are resistant to imipenem.
Thus, the synergism between the peptide and the carbapenem should be interpreted as a consequence
of the ability of peptides to open ways by which imipenem can reach PBPs. Similar scenarios were
seen in the other resistant strains lacking OprD. Moreover, these results pointed out that the injuries in
the outer membrane caused by AMP38 seem to facilitate the entry of imipenem.
FICi values have certain limitations, since they do not give information about the kinetics
of bacterial killing. The results are determined after 24 h exposure to antimicrobials, and thus
represent a fixed picture of the state after the incubation period. Consequently, with this type of
assay, one could disregard the eventual usefulness of antimicrobial combinations for the treatment
of complicated microbial infections. Thus, we have performed a series of experiments in order to
explore the antimicrobial actions during the first steps of the growth cycle. Combinations of sublethal
concentrations of colistin with imipenem failed in increasing bacterial death. On the contrary, the
4 µg/mL concentration of colistin combined with either 0.5 or 4 µg/mL of imipenem markedly
enhanced death, irrespective of imipenem concentration; this is consistent with the hypothesis that
colistin facilitates the entry of carbapenem, and that eventual resistance would be due to restrictions in
the access of imipenem to PBPs (Figure 2A).
Combinations of AMP38 and imipenem enhanced bacterial death. Whereas 8 µg/mL of AMP38
alone had a bacteriostatic effect, the combination of AMP38 (also at 8 µg/mL) plus imipenem (4 µg/mL)
resulted in a bactericidal effect—despite the fact that the MIC of imipenem is 16 and that of AMP38 is
32—although the combination failed to completely eradicate the bacterium (Figure 2C). Meropenem at
1 µg/mL had a bacteriostatic effect, keeping bacteria at 107 CFU/mL. Nonetheless, the combination of
4 µg/mL of AMP38 plus 1 µg/mL of meropenem completely killed bacteria after 6 h of contact.
Time kill-kinetics with sub-lethal amounts of imipenem and AMP38 and assays performed with
meropenem (Figure 2D), as well as those at sublethal concentrations of both AMP38 and imipenem
and combinations of both (Figure 2E,F) confirmed that AMP38 facilitates the entry of imipenem by
disturbing the outer membrane. Figure 3 shows the effect on the mucous 023VH strain growth curve
to be very similar to the results obtained with the rest of strains studied (data not shown).
One of the main goals of antimicrobial chemotherapy is the eradication of biofilms. Stable biofilms
can play a key role in pathogenesis, and this is particularly a matter of concern in respiratory
infections produced by P. aeruginosa. This species is able to produce stable biofilms in many situations,
particularly when causing lung infections. Sessile bacteria living in a biofilm state are generally
more resistant to antimicrobial agents. The ability of combinations of AMP38 and imipenem to
eradicate biofilms was explored. In our experience (data not shown,) the use of colistin to eradicate
biofilms needs concentrations higher than 1000 µg/mL; imipenem’s MBEC is 500 µg/mL, and that of
imipenem is higher than 500 µg/mL, whereas the combination of AMP38 and imipenem was able to
completely eradicate the biofilm at 62.5 µg/mL. Thus, a true synergism of imipenem and AMP38 was
again observed.
TEM has allowed significant advances in the understanding of bacterial structure and eventually
physiology [22], including antibiotic tolerance and biofilm formation. The mechanism of action
of AMP38 in P. aeruginosa and S. marcescens was confirmed by examining untreated and treated
bacteria with transmission electron microscopy. Untreated P. aeruginosa cells were examined by TEM.
Electron micrographs of AMP38-treated P. aeruginosa (Figure 4) show a disorganized outer and inner
membrane, as compared to the smoothness of untreated membranes. As a control, S. marcescens was
used. This bacterium is intrinsically resistant to colistin, because although colistin disorganizes its
outer membrane, it is not capable of altering the inner membrane [23], and the bacterium remains
viable. Typically, the effect of colistin on S. marcescens cells is visualized as the production of blebs.
We performed an ultrastructural analysis via TEM in order to explore whether colistin and AMP38
share mechanisms of action.
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When S. marcescens was exposed to colistin, blebs appeared on the outer layer, but no changes
were visualized in the cytoplasmic membrane (Figure 4). Figure 4 shows S. marcescens exposed to the
AMP38, where the same blebs were observed in the outer membrane. Although further research has to
be done, the microscopically visualized effects of AMP38 and colistin on Gram-negative bacteria seem
to be similar, if not identical.
In conclusion, our data pointed out that the use of synthetic AMPs inspired by natural products
that are potentially less toxic [18] than the natural parent compound may contribute to the rescue of
antimicrobial agents to which some pathogens have become resistant. In this case, it seems feasible to
kill imipenem-resistant Pseudomonas aeruginosa with imipenem when combined with other molecules
(such as AMP38) which are able to sensitize the bacterium to the antibiotic. Since carbapenems remain
the main antimicrobials for treating multidrug-resistant P. aeruginosa infections, and the development
of carbapenem resistance may significantly compromise their efficacy, the use of peptides such as
AMP38 could serve to rescue the use of carbapenems for these purposes. Their use should give
better results than the use of colistin and polymyxins, which have already demonstrated synergistic
effects [24].
4. Experimental Section
4.1. Bacterial Strains, Media, and Antimicrobial Substances
The imipenem-resistant P. aeruginosa PA116136 isolate was obtained from a patient with
chronic pulmonary disease at the Servei de Microbiologia of the Hospital Universitari de Bellvitge
(L’Hospitalet de Llobregat, Barcelona, Spain). It has an insertion sequence (ISPa133) sited just
before nucleotide 697. This interrupts the coding region, producing a loss of OprD expression and
consequently contributes to the resistance to carbapenems [25]. P. aeruginosa 536SJD and 481SJD
isolates were obtained from patients with chronic pulmonary disease at the Servei de Microbiologia
of the Hospital Sant Joan de Déu (Esplugues de Llobregat, Barcelona, Spain). P. aeruginosa 023VH
and 846VH isolates were obtained from cystic fibrosis patients at the servei de Microbiologia of
the Hospital Universitari Vall d’Hebron (Barcelona, Spain). P. aeruginosa ATCC 27853 served as a
control strain in susceptibility tests. Cation-adjusted Mueller–Hinton (CAMHB, Becton, Dickinson and
Company, San Agustin de Guadalix, Madrid, Spain) was used to determine minimum inhibitory
concentrations (MICs) and minimal biofilm eradication concentration (MBEC). Tryptic soy agar
(TSA, Scharlau Microbiology, Sentmenat, Spain) was used for the determination of colony counts
in time-kill assays. Serratia marcescens strain nima [26] was used as a control in electron microscopy.
Imipenem monohydrate, tobramycin sulfate, amikacin sulfate, ciprofloxacin, and aztreonam were
obtained from Sigma-Aldrich (Madrid, Spain); colistin sulphate was kindly supplied from Zhejiang
Shenghua Biok Biology Co., Ltd., (Shanghai, China), and the cyclolipopeptide analog of polymyxin
AMP38 was synthetized by us.
4.2. Peptide Synthesis and Purification
The synthesis of peptide AMP38 was performed manually following standard Fmoc/tBu
procedures using DIPCDI/HOBt activation on Rink amide resin. Once the sequence was assembled,
cleavage of the peptide from the resin was carried out by acidolysis with Trifluoroacetic acid
/triisopropylsilane/water (95:3:2, v/v) for 90 min. TFA was removed with a stream of nitrogen
gas. The oily residue was treated with dry diethyl ether, and the precipitated peptide was isolated
by centrifugation. The homogeneity of the crude peptide was assessed by analytical HPLC
on Nucleosil C18 reverse-phase columns (4 mm× 250 mm, 5 µm particle diameter, and 120 Å
porous size). Elution was carried out at 1 mL·min−1 flow with mixtures of H2O containing 0.045%
TFA and acetonitrile containing 0.036% TFA, with UV detection at 220 nm. Cyclization of the
peptide was carried out in 5% dimethylsulphoxide aqueous solution for 24 h and lyophilized twice.
The peptide was subsequently purified by preparative HPLC on a Waters DeltaPrep 3000 system with
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a Phenomenex C18 [18,27–29] column (250 mm × 10 mm, 5 µm) eluted with H2O/acetonitrile/0.1%
TFA gradient mixtures and UV detection at 220 nm. Final purity was greater >99% according to
analytical HPLC. The peptide was characterized by matrix-assisted laser desorption ionization time
of flight (MALDI-TOF) mass spectrometry with a PerSeptive Biosystems Voyager-DE instrument.
MALDI-TOF MS, m/z (C55H96N16O12S2): 1237.9 [M + H]+, 1259.7 [M + Na]+, 1275.7 [M + K]+,
1219.9 [M − H2O]+ (Figure 1).
4.3. Determination of Minimum Inhibitory Concentrations
MIC values were determined by broth microdilution method and interpreted according to
European Committee on Antimicrobial Susceptibility Testing EUCAST guidelines [30].
4.4. Synergy Study
A checkerboard test was used to determine the fractional inhibitory concentrations (FICs) of
colistin in combination with the peptide AMP38. Each well in a 96-well plate was inoculated with
100 µL of a bacterial inoculum of 1 × 105 CFU/mL, and the plates were incubated at 37 ◦C for 24 h.
The FIC was calculated after identifying the first well in each row without growth (MIC), according the
following formula: FIC of drug A (FIC A) = (MIC of drug A in combination)/(MIC of A); FIC of drug
B (FIC B) = (MIC of drug B in combination)/(MIC of B). The FIC index (FICi) values were calculated
by adding the FIC of imipenem to the FIC of AMP 38. FICi values were interpreted as follows [21]:
FICi < 0.5, synergistic; FICi ≥ 0.5 and < 4, no interaction; FICi > 4, antagonistic [31].
4.5. Time–Kill Curves
Killing curve assays were performed with a starting inoculum of 6 × 106 CFU/mL. Strains were
tested against colistin, imipenem, meropenem, tobramycin, amikacin, ciprofloxacin, aztreonam,
and AMP38 alone and in all possible combinations at concentrations above and below the MICs.
Antimicrobials were added to 10 mL of bacteria in the exponential phase of growth and incubated at
37 ◦C with shaking. Samples were obtained aseptically at 0.5, 1, 2, and 4, diluted in Ringer 1/4 and
plated on TSA for colony counting. The response of microbial strains to a single antimicrobial and to
the combinations of pairs of antimicrobials was determined by lowering logarithms of viable bacteria.
In accordance with Lora-Tamayo et al. [26], an antimicrobial was considered active when a
reduction of ≥1 log10 relative to the initial inoculum was observed. A combination of antimicrobials
was considered synergistic when a reduction of ≥2 log10 was observed with respect to the most
active antimicrobial. A combination of two antibiotics was considered additive when the logarithm of
reduction was between 1 and 2.
4.6. Transmission Electron Microscopy
Both P. aeruginosa PA116136 and S. marcescens nima strains were observed by TEM after treatment
with AMP38 or colistin, using untreated bacteria as controls. Bacteria in the exponential phase
of growth were centrifuged at 8000× g for 10 min to obtain a concentration of 108 CFU/mL.
Pellets were then suspended in Tripticase Soy Broth (TSB) and antimicrobials were added (300 mg/L for
S. marcescens and 100 mg/L for P. aeruginosa for both colistin and AMP38). Bacteria were incubated
for 20 min at 37 ◦C and harvested by centrifugation. Bacteria were cryo-immobilized by using a
Leica HPM100 high-pressure freezer (Leica, Vienna, Austria). Frozen samples were freeze-substituted
(Leica Microsystems, AFS2) for 72 h at −90 ◦C. Temperature was gradually increased to 4 ◦C, and then
samples were stored at room temperature. Substitutions were performed in pure acetone containing 2%
(w/v) osmium tetroxide and 0.1% (w/v) uranyl acetate. Afterwards, samples were washed with acetone
and gradually infiltrated in a resin Epon. Samples were embedded in fresh Epon and polymerized at
60 ◦C for 48 h. Ultrathin sections (50–70 nm) were made with the Leica Ultracut UC6 (Leica, Vienna,
Austria). Epon-embedded thin sections were examined in a JEM1010 JEOL transmission electron
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microscope (JEOL Ltd., Tokyo, Japan) by working with a tungsten filament at 80 kV. Images were
acquired with the software Analysis (version 3.2, Soft Imaging System GmbH, Münster, Germany).
4.7. MBEC Determination
Minimal biofilm eradication concentration (MBEC) determinations were conducted as described
by Moskowitz et al. [32] with a few modifications. Briefly, bacterial biofilms were formed by immersing
the pegs of a modified polystyrene microtiter lid (catalog No. 445497; Nunc TSP system) into 96-well
microtiter plates containing 200 µL of CAMHB each, followed by incubation at 37 ◦C for 24 h in static
conditions. Pegs were then gently rinsed in 0.9% NaCl solution, and biofilms were exposed to different
concentrations of antimicrobials for 24 h at 37 ◦C. Pegs were again rinsed with 0.9% NaCl solution
and biofilms were removed by 10 min sonication. Recovered bacteria were incubated for 24 h at
37 ◦C. Optical densities at 620 nm were measured in order to determine MBEC values, defined as
the lowest concentration of antimicrobial that prevented bacterial regrowth from the treated biofilm.
All experiments were performed in triplicate.
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Background: Staphylococcus aureus, including ‘superbug’ MRSA, is a major cause of nosocomial infections. In
the European Union, up to 171 200 new nosocomial MRSA infections are acquired annually, and in the USA S. aur-
eus causes more deaths than HIV/AIDS and tuberculosis combined. MRSA is also the first group of pathogens
that infect the pulmonary tract in young patients with cystic fibrosis.
Objectives: We describe two newly developed and synthesized colistin (polymyxin E)-inspired molecules.
Methods: A collection of several isolates of S. aureus [including MRSA and vancomycin-resistant S. aureus
(VRSA)] was tested. To check the antimicrobial activity, we performed time–kill curves, growth curves, biofilm
eradication, toxicity and isothermal titration calorimetry.
Results: Both peptides showed high antimicrobial activities (MIC 4 mg/L) and low relative toxicities (selectivity
index close to 23).
Conclusions: Successful production of polymyxin-scaffold molecules active against S. aureus, both MRSA and
VRSA, opens up new approaches to the treatment of these complicated infections.
Introduction
Among the world’s most dangerous ‘superbugs’ are MDR bacteria
of the so-called ESKAPE group.1,2 The proportion of these bacteria
in common infections has increased recently.3 Moreover, patients
with vascular prostheses, indwelling catheters, dialysis shunts,
etc., are particularly vulnerable to the virtually untreatable infec-
tions resulting from ESKAPE colonization and subsequent biofilm
formation.
The indiscriminate use of penicillin has increased the percent-
age of penicillin-resistant Staphylococcus aureus strains to nearly
100%.4 The same is true for several other antibiotics.
Overexpression of penicillin-binding protein 2A in MRSA enables
survival in the presence of high concentrations of b-lactams,
including methicillin.5 Isolates with intermediate or full resistance
to vancomycin emerge.4 Owing to this, antimicrobial peptides
(AMPs) have become very important drugs in the treatment of
Gram-positive infections. None the less, strains resistant to AMPs
have been recently identified.
Amphipathic polymyxins are cationic non-ribosomal antimicro-
bial peptides (CAMPs) produced by Paenibacillus polymyxa that be-
came available as antimicrobials in 1949 and were subsequently
abandoned because of their nephrotoxicity and neurotoxicity.6
However, colistin and polymyxin B have recently been rehabilitated
for the treatment of infections caused by MDR Gram-negative
organisms, mainly Pseudomonas aeruginosa and Acinetobacter
baumannii.7 Although polymyxins interact with the negatively
charged outer membrane of Gram-negative bacteria,8 their mech-
anisms of action may additionally include alterations in ribosome
binding, respiration, cell division, cell structure and the production
of reactive oxygen species.9 Gram-positive organisms lack an outer
membrane and are thus naturally resistant to polymyxins.
The synthesis of new molecules that are less toxic and have
greater activity than conventional antibiotics is challenging. One
strategy is to make small changes in known molecules, such as
polymyxin, to generate derivatives effective against Gram-positive
bacteria. The antimicrobial activity of two novel synthetic cyclolipo-
peptide analogues of polymyxin (CAMP113 and CAMP207) against
S. aureus and other Gram-positive bacteria is reported here.
Materials and methods
Bacterial strains and growth conditions
The clinical S. aureus strains used are listed in Table S1, available as
Supplementary data at JAC Online. S. aureus ATCC 29213 and ATCC MRSA
VC The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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700698 served as controls. Mueller–Hinton (Becton, Dickinson and
Company, Madrid, Spain) broth was used to determine MICs and minimal
biofilm eradication concentrations (MBECs), tryptic soy agar for colony
counting and tryptic soy broth (Scharlau Microbiology, Sentmenat, Spain)
with 0.25% glucose for biofilms. Colistin sulphate was supplied by Zhejiang
Shenghua Biok Biology Co., Ltd (Shanghai, China). Other antibiotics were
from Sigma–Aldrich (Madrid, Spain). The cyclopolypeptides CAMP207 and
CAMP113 were synthesized in our laboratory as described below.
Peptide synthesis and purification
Peptides CAMP113 and CAMP207 were synthesized manually following
standard Fmoc/tBu methods and characterized by MALDI-TOF MS using a
PerSeptive Biosystems Voyager-DE instrument [MALDI-TOF MS: m/z
(C55H96N16O12S2): 1237.9 (M!H)!, 1259.7 (M!Na)!, 1275.7 (M!K)!,
1219.9 (M#H2O)!] (Figure 1).
10
MIC determination
Broth microdilution was used and interpreted according to EUCAST
guidelines.11
Time–kill curves and growth curves
Killing curves were obtained with a starting inoculum of 5%105 cfu/mL
against CAMP113 and CAMP207. Antimicrobials were added to exponential-
ly growing bacteria at 37C with shaking. Samples were retrieved aseptically
at 1, 2, 4 and 6 h, diluted in 1=4% Ringer and plated on tryptic soy agar. The
response to a single antimicrobial was determined based on a logarithmic
decrease in viable bacteria. The effect of CAMPs on the growth of clinical
S. aureuswas assayed with starting inocula of 106 and 108 cfu/mL.
MBEC determination
Bacterial biofilms were formed by immersing the pegs of a modified poly-
styrene microtitre lid (catalogue no. 445497; Nunc TSP system) into 96-well
microtitre plates containing 200lL of medium and incubated 37C for 24 h.
Pegs were gently rinsed in 0.9% NaCl solution, and biofilms exposed to
CAMPs. Pegs were again rinsed with 0.9% NaCl solution and biofilms
removed by sonication. Recovered bacteria were incubated for 24 h at
37C. Optical densities at 620 nm were determined. MBEC is defined as the
lowest concentration of antimicrobial that prevented bacterial regrowth
from the treated biofilm.
Toxicity of peptides in human hepatocytes
Colistin, CAMP113 and CAMP207 were assayed for in vitro toxicity against
human hepatocytes (HepG2) as previously described.12
Confocal laser scanning microscopy imaging
Biofilms were washed with 1=4% Ringer and treated with antimicrobials.
After 4 h of incubation (37C), biofilms were rinsed with 1=4% Ringer and
stained using the Live/Dead BacLight kit (Thermo Fisher Scientific,
Eugene, OR, USA). Fluorescence was observed using a Leica TCS-SL fil-
ter-free spectral confocal laser-scanning microscope (Leica
Microsystems, Mannheim, Germany) equipped with a 488 nm argon
laser and 543 and 633 nm He/Ne lasers. All experiments were
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performed in duplicate. The images were analysed using ImageJ soft-
ware (NIH, Bethesda, MD, USA). The percentages of live and dead bac-
terial cells were calculated from the total cell number.
Results and discussion
Peptides CAMP113 and CAMP207 have a disulphide bond between
two cysteine residues. Moreover, they contain a dodecanoyl chain
instead of (S)-6-methyloctanoyl, have a Cys residue at position 4,
norleucine (NLe) at position 7 and (D)-Cys at position 11, instead of
2,4-diaminobutyric acid, Leu and Thr of polymyxin. CAMP113 was
further modified with (D)-Phe and CAMP207 with (D)-(4F)-Phe in-
stead of Leu at position 6. In addition, an Arg was substituted at
position 8 of CAMP113 whereas colistin contains 2,4-diaminobuty-
ric acid (Figure 1).
Polymyxin action involves interaction with lipid A and the dis-
placement of Mg2! and Ca2! bridging adjacent LPS molecules.13
The MIC of both peptides was 4 mg/L. Tested strains were resistant
to colistin (.512 mg/L) and susceptible to vancomycin (1–0.5 mg/
L), except for SasVR (Table S1). The activity of the two CAMPs was
high, their MICs being within the clinical use range. MIC values rep-
resent only the cumulative effect at 18 h, rather than the time
course of activity, whereas time–kill kinetics or growth curves de-
scribe the antimicrobial action, providing insights into the events
during its first hours and depicting the biological behaviour over
time. As expected based on their chemical similarities both pepti-
des killed the bacteria in a concentration-dependent manner
(Figure 2), their behaviour being very similar irrespective of the
strain tested.
Two types of responses were observed in the presence of
CAMPs: either the bacterium was completely inhibited at all con-
centrations tested or inhibition was achieved only at high concen-
trations (Figure 2). Neither peptide was able to eradicate fully the
bacteria solely as a function of its concentration; rather, the activ-
ities of the two CAMPs strongly depended on the bacterial strain.
For example, CAMP113 fully eradicated strain SaS06 (Figure 2a) in
1 h at 16 mg/L and in 2 h at 8 mg/L, but a few individual bacteria
survived at 4 mg/L whereas strain SaS16 was completely eradi-
cated at this latter concentration (Figure 2). At a concentration of
8 mg/L or higher, CAMP113 produced the rapid death of strain
SaS16 (Figure 2c) during the first hour whereas at an equal concen-
tration of CAMP207 (Figure 2) 2 h was required. At 4 mg/L, both
peptides required 4 h to kill fully the strain SaS16. In tests of strain
SaS18, complete eradication was achieved within 4 h using 8 mg/L
CAMP113 but within 6 h using the same concentration of CAMP207
(Figure 2f). However, even at 4 mg/mL, CAMP207 completely failed
to eradicate SaS18. Similar outcomes were obtained with the re-
mainder of the tested strains.
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Figure 2. Antimicrobial activity of CAMP113 and CAMP207. (a) Strain SaS06 incubated with CAMP113. (b) Strain SaS06 incubated with CAMP207. (c)
Strain SaS16 incubated with CAMP113. (d) Strain Sas16 incubated with CAMP207. (e) Strain Sas18 incubated with CAMP113. (f) Strain Sas18 incubated
with CAMP207. (g) Growth curve of strain SaS16 (inoculum of 106 cfu/mL) in the presence of CAMP113. (h) Growth curve of strain SaS06 (inoculum of
108 cfu/mL) in the presence of CAMP207.
Synthetic polymyxins kill Gram-positives JAC
3 of 6
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/advance-article-abstract/doi/10.1093/jac/dky366/5095202 by U
niversitat de Barcelona. C
R
AI user on 30 Septem
ber 2018
Figure 2 also shows representative growth curves. With inocula
up to 2%106 cfu/mL, growth was fully prevented irrespective of the
CAMP and the concentration tested (4, 8 or 16 mg/L). Higher inoc-
ula (up to 2%108 cfu/mL) gave initial growth delay at 4 mg/L, and a
longer delay at 8 mg/L. Finally, both CAMPs were able to inhibit fully
the growth at concentrations of 16 mg/L, demonstrating the con-
centration dependence.
S. aureus have evolved mechanisms to evade innate host
defences including proteolysis of natural peptides, secretion of lytic
enzymes, modulation of the electrical charge of the cell surface to
enhance repulsion, and biofilm formation.14 Biofilms have been
the focus of considerable research attention and their destruction
the main goal of current antibacterial therapy. The MBECs of both
CAMPs indicated the ability of these compounds to eradicate fully
the S. aureus biofilms at relatively low concentrations, in contrast
to colistin, which had no effect. Confocal imaging (Figure 3)
revealed the effects of the CAMPs (at 128 mg/L) on S. aureus bio-
film during short exposure periods (4 h). No significant death
occurred in either the controls or colistin-treated biofilms, whereas
CAMP113 and CAMP207 were able to kill roughly one-half the bac-
teria within the biofilm (47.27% and 50.46%, respectively). Given
the current interest in CAMPs in the search for new approaches in
anti-biofilm treatment,15 our study demonstrates the potency
of these peptides in targeting biofilms of several clinical isolates of
S. aureus. Under conditions in which a colistin dose of 2048 mg/L
was required, CAMP113 and CAMP207 eradicated the biofilms of
all strains tested at much lower concentrations (Figure 3).
The CAMPs were also tested for their cytotoxicity in the human
hepatocellular cell line HepG2 (ATCC HB8065). As shown in
Figure 4, colistin had relative low cytotoxicity in vitro as its mechan-
ism of toxicity involves the accumulation of molecules in organs
such as the kidney. At 5 mg/L, a slightly higher concentration than
the MICs of the CAMPs, none of the tested compounds had detect-
able toxicity. A concentration of 50 mg/L yielded 89.49% HepG2
cell viability for colistin and 67.03% and 62.62% for CAMP113 and
CAMP207, respectively. At 100 mg/L, colistin resulted in 68.75%
HepG2 viability, CAMP113 53.2% and CAMP207 57.3%. At an anti-
microbial concentration of 250 mg/L, HepG2 viability was 51.05%,
16.01% and 8.29%, respectively. At 500 mg/L, whereas 38.39% of
the cells survived in the presence of colistin both CAMP113 and
CAMP207 were highly toxic (7.74% and 7.4%, respectively)
(Figure 4). None the less, the selectivity index (the relationship be-
tween the IC50 and the MIC) in S. aureus strains
16 was inordinately
high for the peptides (21.25 for CAMP113 and 23.75 for CAMP207
compared with 0.36 for colistin), i.e. CAMP113 and CAMP207 are
much more selective than colistin because the concentrations
needed to kill the bacteria are much lower. Moreover, colistin is
nephrotoxic, as it increases tubular epithelial cell membrane
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Figure 3. (a) Minimal biofilm eradication concentration assays. Strain SaS06 (CAMP113, 128 mg/L; CAMP207, 128 mg/L; colistin .2048 mg/L). Strain
SaS16 (CAMP113, 32 mg/L; CAMP207, 32 mg/L; colistin .2048 mg/L). Strain SaS18 (CAMP113, 256 mg/L; CAMP207, 256 mg/L; colistin, .2048 mg/L);
(b) Percentage of biofilm death after 4 h of exposure; (c) Confocal laser scanning microscopy assays. Images (1024%1024 pixels) were taken after 4 h of ex-
posure to: control, colistin, CAMP113 or CAMP207. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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permeability to cations, anions and water, leading to cell swelling
and cell lysis.17 The presence in the newly synthesized CAMPs of a
disulphide bond facilitates their biodegradation and thus avoids
their accumulation in the kidney. This is in agreement with previ-
ous studies, in which the LD50 for peptides of this family in CD-1
mice was 283 mg/kg, compared with the 59.5 mg/kg determined
for polymyxin.10
The emergence of MDR strains of several species has posed a
tremendous challenge in clinical practice and renewed interest
in polymyxins, whose activity against Gram-negatives is well
established. Colistin is considered the drug of last resort in the
treatment of Gram-negative MDR bacteria such as P. aerugi-
nosa, A. baumannii and Klebsiella pneumoniae.18,19 None the
less polymyxins are intrinsically inactive against Gram-positive
bacteria because they lack lipid A, the primary binding site of
polymyxins.18,20
Novel peptides synthesized in an attempt to evade the increas-
ing polymyxin resistance of Gram-negative bacteria have low MIC
values in Gram-positive organisms.8 Similarly, our peptides
showed activity against S. aureus. Teichoic acids have a chemical
structure similar to that of the LPS regions to which polymyxins
bind.15 To determine whether teichoic acids were the targets of
CAMP113 and CAMP207, we performed isothermal titration calor-
imetry experiments. The results showed a three-step reaction be-
tween the peptides and teichoic acid, two of which were exergonic
and the third endergonic (Figure S1).
To examine the spectrum of action of the CAMPs studied, we
explored their action against Gram-positive Streptococcus
pneumoniae. Our results showed that in this species the MIC of
colistin was consistently .32 mg/L, whereas the MICs of both
our peptides were between 2 and 4 mg/L depending on the
isolate.
Polymyxins, regarded as inactive against Gram-positive organ-
isms, after some small changes, have activity against S. aureus
and S. pneumoniae; subject to more detailed determination of
in vitro and in vivo toxicity as well as the development issues, pepti-
des of this type may open up new frontiers in the treatment of ‘un-
treatable’ infections.
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Abstract: The emergence of antimicrobial resistance due to the overuse of antimicrobials together 
with the existence of naturally untreatable infections well demonstrates the need for new instruments 
to fight microbes. Antimicrobial peptides (AMPs) are a promising family of molecules in this regard, 
because they abundantly occur in nature and the results of preliminary studies of their clinical 
potential have been encouraging. However, further progress will benefit from the standardization of 
research methods to assess the antimicrobial properties of AMPs. Here we review the diverse 
methods used to study the antimicrobial power of AMPs and recommend a pathway to explore new 
molecules. The use of new methodologies to quantitatively evaluate the physical effect on bacterial 
biofilms such as force spectroscopy and surface cell damage evaluation, constitute novel approaches 
to study new AMPs. 
Keywords: antimicrobial peptides; bacteria; protozoan; fungi; atomic force microscopy; confocal 
microscopy; growth curves; death kinetics 
 
1. Introduction  
Bacteria are the leading cause of infections worldwide but they affect individuals in developed 
and third world countries in different ways. In the latter, most bacterial infections are those known as 
classical, whereas in developed areas hospitalized patients or individuals who have undergone 
medical treatments, such as surgery, solid organ transplantation, and anticancer treatments, are the 
most vulnerable. In recent years, the progressive increase in the incidence of multidrug-resistant 
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bacterial infections has raised concern. In 2014, the office of the President Obama published a 
detailed report on antimicrobial resistance, leading to the publication, on September 18, 2014, of an 
Executive Order entitled ―Combating Antibiotic-Resistant Bacteria‖ 
(https://obamawhitehouse.archives.gov/the-press-office/2014/09/18/executive-order-combating-antib
iotic-resistant-bacteria). This document included sections on new policies, changes in funding, and 
recommendations, among others. Following the election of Donald Trump, more than 30 scientific 
and social alliances and societies signed a document in which they expressed the hope these 
investments would be maintained and even expanded. Also in 2014, the World Health Organization 
(WHO) published, an extended report calling attention to this crucial health problem 
(www.who.int/drugresistance/documents/surveillancereport/en/). Bacterial resistance to antimicrobials 
has likewise attracted the attention of the governments of several other countries.  
However, antibiotics research had an erratic history. The clinical use of antimicrobials started 
approximately in 1932, with the release of Prontosil (an antibacterial drug discovered at Bayer 
Laboratories, Germany), a molecule with a lethal effect on gram-positive cocci. Prontosil was the 
first sulphonamide and it ushered in the antibiotic era. Thereafter, new antibiotics were rapidly 
discovered, including penicillin and streptomycin, and became available for clinical use. 
Recently, due mostly to economic, rather than to medical or scientific reasons, the pipeline of 
novel antimicrobial molecules under development has mostly closed [1]. Instead, most of the drugs 
under development are improved derivatives of those already on the market. This has had several 
non-negligible consequences. Firstly, modified compounds, while frequently enlarging the spectrum 
of drug activity or enhancing its antimicrobial effect, do not change the target, including the 
resistance mechanisms promoted in organisms exposed to these agents. New molecules, acting 
through newly recognized mechanisms of action and on different targets, are expected to be much 
more effective, but very few have been developed over the past several years. The recent emergence 
of new mechanisms of resistance and the scarcity of novel antimicrobial products able to target them 
account for the current growing concern and the revival of research efforts.  
The main sources of the thousands of antibiotics discovered during the golden era of antibiotics 
were soil bacteria and fungi. In fact, antibiotics were long regarded as defense mechanisms of soil 
microbes, although this function has yet to be definitively demonstrated in nature [2]. Although the 
further exploration of natural products for their antibiotic activities is expensive and the chance of 
successes limited, the identification of not previously appreciated delivery methods or products, 
including those derived from natural molecules, will open up new research perspectives regarding 
antimicrobials [3–7].  
Once a candidate molecule has been synthesized and purified, its properties, activities, and 
efficacy, but also its toxicity, must be investigated at the biological level. Clearly, a drug should exhibit 
greater toxicity towards microorganisms than on its human hosts. Moreover, not only bacteria but also 
fungi and protozoa produce infections. Therefore, in the process of exploring the antimicrobial action 
of a new molecule, the possible effect on other infectious microbes should be investigated as well. 
This review examines the main methods used to investigate new antimicrobials and, in the form 
of a flow diagram presented at the end, describes the main criteria for their development.  
2. Minimum inhibitory concentration 
The minimum inhibitory concentration (MIC) is a parameter widely used to assess the 
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susceptibility of microbes. It is defined as the lowest antimicrobial drug concentration that prevents 
visible growth of the microorganism after an overnight incubation. An advantage of the MIC is that it 
is quantitative and, if standardized procedures are used, the values obtained by different laboratories 
can be compared. Moreover, national agencies, mainly the USA’s Clinical and Laboratory Standards 
Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
have published cut-off points based on criteria that are relatively homogeneous worldwide.  
Either solid (incorporating antimicrobials into the agar medium) or liquid medium can be used 
to determine MIC values. Liquid medium tests are conducted using either the microdilution (96-well 
microtiter plates) or the macrodilution (test tubes) method. However, while an excellent parameter 
for clinical purposes, the MIC has serious limitations in research. First, the inoculum density strongly 
influences the MIC value. Second, the definition of the MIC is vague, as, for example, neither 
―visible growth‖ nor ―overnight‖ (typically 18 h) is well-defined. Moreover, visible growth is 
determined with the naked eye, and the MIC is a fixed value determined after 18 h of incubation. 
However, while the presence of visible growth after 18 h should be interpreted as a lack of 
antimicrobial action, this may not precisely be the case, as illustrated by a simple theoretical example: 
Microbe A is susceptible to 4 µg of drug X/mL, and a fully resistant isolate (B) is resistant to 200 µg 
of drug X/mL. After incubation of microbes A and B in medium containing 4 µg X/mL, the growth 
was visible in both tubes (Figure 1), but the history of the cultures is completely different. Whereas 
the growth of culture B started immediately, as in the control experiment, culture A was inhibited for 
the first 12 h, during which time the antibiotic concentration was >3 µg/mL, but began to grow 
thereafter. This is frequently referred to as ―regrowth‖ and is discussed controversially, although its 
existence demonstrates the weakness of MIC as a parameter. Moreover, antimicrobial action may be 
bactericidal, in which the peptide kills the bacterium, or bacteriostatic, in which bacterial growth is 
completely inhibited (Figure 2). These two mechanisms can be distinguished by plotting a growth 
curve of the bacterium in the presence and absence of antimicrobials. 
 
Figure 1. Comparison of the growth curves of different bacteria in the presence of an 
antibacterial agent added at 4 h. The growth kinetics of a control culture (open triangles), 
a resistant microbe (filled triangles), a moderately susceptible microbe (open circles), and 
a fully susceptible microbe (filled circles) are shown. Filled squares represent 
antimicrobial concentration. 
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Figure 2. Growth kinetics of a bacterium in the presence of a bacteriostatic (open circles) 
and a bactericidal (filled triangles) agent. 
3. Minimal biocidal concentration 
A much more easily defined and informative parameter is the minimal biocidal concentration 
(MBC): the lowest concentration of an antimicrobial agent required to kill a particular bacterium. 
Bacterial killing is confirmed when the test culture contains no growing cells. However, the MBC 
also depends on the chosen methodology. For instance, growth is a function not only of the 
experimental conditions but also the metabolic state of the bacterium. Thus, bacteria may be viable 
but non-cultivable (VBNC) due to their poor metabolic activity. Nonetheless, while unable to divide, 
they are still alive because under the appropriate conditions allowing their ―resuscitation‖ they are 
―re-cultivable‖. VBNC unable to grow in standard medium are smaller and have lower levels of 
nutrient transport, ATP production, and macromolecular biosynthesis but they may still be able to 
survive for as long as one year [8]. Clinically, VBNC may be the source of recurrent infections but 
they are not taken into account in MBC determinations. Furthermore, experimental MBC values are 
often beyond the limits that are pharmacologically achievable in a therapeutic setting; thus, the MBC 
is mostly valuable in theoretical studies, not in clinical microbiology. Furthermore, whether an 
antimicrobial is biostatic or biocidal in most cases strongly depends on its concentration. 
4. Growth curves 
In the search for new antimicrobials, an understanding of the dynamic interactions between the 
putative drug and the microorganism is clearly important. The activities of natural and synthetic 
peptides can be easily followed by plotting a growth curve, that is, a graphical representation of the 
growth of the bacterium of interest in a freshly inoculated culture. During the exponential phase, 
growth proceeds at a maximal rate (µmax), which depends upon the characteristics of the 
bacterium and the environmental conditions, including temperature, oxygen availability (for some 
bacteria), light, medium composition, etc. The growth rate (µ) can be calculated as Nt = N0 × e
µt
 and 
thus as µ = (lognNt − lognN0)/t, where Nt is the number of individuals at time t and N0 the number of 
individuals at time 0. The exponential phase of growth is followed by a transition phase in which µ 
decreases until it reaches 0, marking the stationary phase. For a given microbe cultured under 
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standardized conditions, the growth curve is highly reproducible whereas the addition of an 
antimicrobial disrupts the growth curve. When added during the exponential phase, antimicrobials 
can be evaluated as bacteriostatic or bactericidal (Figure 2). Although, in principle, the desired effect 
of an antimicrobial is bactericidal rather than bacteriostatic, this is not universally true. Many 
bacteriostatic antimicrobials are excellent therapeutic agents because they promote host defense 
mechanisms, which help to eradicate the bacterium. Furthermore, bacteriostatic agents can also be 
used to prevent nosocomial infections as well as infections in indwelling medical devices.  
5. Death kinetics 
The best way to accurately determine the pharmacodynamics of drug is to plot a so-called 
time-kill curve. The drug under study is added to a starting bacterial inoculum of 10
6
 CFU/mL in 
MHBCA (Muller-Hinton broth cation adjusted) medium, and parallel experiments adding 25% 
mammal serum; at different times, aliquots are retrieved aseptically for bacterial counting.  
The advantage of a time-kill curve is that provides a dynamic picture and thereby avoids the 
limitations of fixed time-point studies (Figure 3). Information on the behavior of a drug during its 
first hours of bacterial contact is extremely important, if only the initial and final time-points are 
analyzed, the different intervening processes will be missed, as described for the MIC. 
 
Figure 3. Death kinetics of two antimicrobials: one slow-acting (open circles) and the 
other fast-acting (filled circles). 
Death kinetics can also be used to test for possible synergies between two or more compounds. 
Synergism occurs when a drug combination results in a reduction of the bacterial counts by two or 
more logarithms (decimal) compared to the most active drug alone. A reduction of less than two 
logarithms indicates an additive relationship. A null logarithmic reduction is called indifference, 
whereas antagonistic effects are reflected by an increase of the bacterial counts by two or more 
logarithms compared to the counts obtained with each drug separately (Figure 4). In many cases, 
these data reinforce those obtained by checkerboard (see Section 6). 
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Figure 4. Comparison of the time-kill curves of bacteria incubated in the presence of 
various antimicrobials (A means the antimicrobial alone). 
6. Antimicrobial peptide interactions 
The interaction between peptides and other antimicrobials, or between two antimicrobial 
peptides (AMPs) can be determined quantitatively from the fractional inhibitory concentration (FIC) 
using the checkerboard technique. The FIC of drug A can be calculated as: (FIC A) = (MIC of drug A 
in combination)/(MIC of A), and the FIC of drug B as: (FIC B) = (MIC of drug B in 
combination)/(MIC of B). The FIC index (FICi) is calculated by adding FIC A and FIC B. FICi < 0.5 
indicates a synergistic interaction, FICi values between 0.5 and 4 no interaction, and FICi > 4 an 
antagonistic interaction. Together with calculation of the FICi, determinations of death kinetics 
provide a useful tool to explore drug interactions whereas growth curves reveal the interactions 
between two or more antimicrobials. Figure 5 shows an example in which the synergistic effect of 
imipenem and a newly synthesized AMP (amp38) was determined [9]. 
 
Figure 5. Effect of the control (filled circles), 4 µg imipenem (IMI)/mL (open circles), 8 µg 
AMP38/mL (filled triangles), and 8 µg AMP38/mL + 4 µg IMI/mL (open triangles) on 
Pseudomonas aeruginosa strain PA116136 [9]. 
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In fact, AMPs have been described as synergistic agents with a wide variety of antimicrobials. 
The inhalation therapy of respiratory infections suffered by cystic fibrosis patients demonstrate 
strong antimicrobial synergy of Polymyxin B in combination with silver nanoparticles [10]. 
Moreover, in fungal infections treatment, AMPs are also regarded as candidates to act through 
synergistic effect with already known antifungals. A good example is Ctn (15–34), a 
carboxyl-terminal fragment of crotalicidin (a cathelicidin from the venom gland of a South American 
rattlesnake), the molecule has per se a certain antifungal activity, but an enhancement of antifungal 
properties was found when combined with amphotericin B [11]. Even looking at viruses different 
examples of synergism have been reported. It has been shown that synergy emerges when Env (a 
protein involved in HIV penetration) engages multiple co-receptors prior to inducing fusion and 
when high-affinity inhibitory peptides are present [12]. Finally, it is worthy to mention that such 
synergistic effects have been demonstrated even between AMPs and inorganic molecules. This is the 
case of carbon monoxide-releasing molecules (CORMs): a novel class of compounds (for example 
the light-activated metal complex [Mn(CO)3(tpa-κ3N)]Br) they have shown high synergism with 
some AMPs such as colistin [13]. This strongly suggests the need to explore interactions when 
exploring new AMPs, since even when antimicrobial activity may be weak, their use as enhancers of 
antimicrobial action of others may restitute their interest. One more question should be addressed 
when taking into account that, at least in one case, AMPs have been found to be potentially useful to 
eradicate biofilms and to increase susceptibility to already known antimicrobials [14].  
7. Measuring the efficacy of AMPs against biofilms 
Traditional antimicrobial susceptibility tests (from disk diffusion to broth microdilution methods) 
used to calculate the MIC and thus to define the susceptibility breakpoints predicting therapeutic 
success are performed mostly using planktonic bacteria. However, planktonic microbes are very 
infrequent in infections. Rather, most infectious diseases are caused by bacteria living in a biofilm, 
usually attached to a surface or an interface. Within the biofilm, the bacteria are embedded within a 
slimy extracellular matrix of bacterial origin and they adhere to each other [15]. Biofilm bacteria 
have a much greater resistance to antimicrobials than their planktonic counterparts [16] and the 
corresponding susceptibility breakpoints have not been established [17]. This difference in 
antimicrobial susceptibility between planktonic and biofilm populations of the same organism is due 
to differences in the diffusion of antimicrobials and to complex physiological changes in biofilm 
microbes [18,19]. Thus, for biofilm infections, using the MIC to predict the success of antimicrobial 
treatment is often ineffective, such that susceptibility tests for biofilm-growing bacteria are needed. 
The most relevant parameters currently used to evaluate the in vitro antimicrobial activity of 
antimicrobial compounds in biofilm-growing bacteria are the minimal biofilm eradication 
concentration (MBEC) and the biofilm prevention concentration (BPC) [20]. The effect of 
antimicrobial compounds on the viability and physical stability of the biofilm can be studied with 
confocal laser scanning microscopy (CLSM) and atomic force microscopy (AFM), respectively [21,22]. 
8. Minimal biofilm eradication concentration  
Given the serious challenges associated with infections caused by biofilm microbes and the role 
of biofilms in promoting recurring infections [23], the development of accurate methods to evaluate 
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the efficacy of new antimicrobial compounds against biofilms is crucial. 
The MBEC is defined as the lowest concentration of antibiotic required to eradicate the biofilm [24], 
in other words, the lowest concentration preventing bacterial regrowth from the treated biofilm.  
The MBEC assay uses the Calgary biofilm device (CBD), a 96-well plate with pegs or 
projections built into the lid [24]. Each peg provides a surface for bacterial adhesion, colonization, 
and the formation of a uniform biofilm. The lid is used in conjunction with special troughs for 
growing, washing, and incubating the bacteria. The growing microorganism are cultured in an 
opportune growth medium and allowed to form biofilms on the pegs for 4 to 24 h (depending on the 
specific bacterial growth rate). Bacterial motility greatly influences biofilm formation on the pegs, 
such that more motile microorganisms, which have a greater tendency to aggregate, form robust 
biofilms on the pegs [25]. For example, microorganisms such as Pseudomonas aeruginosa and 
Escherichia coli are flagellated and motile and form high-density biofilms on CBD pegs [26,27] 
whereas non-motile Staphylococcus aureus is much less effective in biofilm formation [28]. 
Once the biofilms are formed, the pegs are rinsed and placed onto flat-bottom microtiter plates, 
where they are incubated for 18–20 h at 37 °C in the presence of different concentrations of 
antimicrobials. Then, the pegs are again rinsed and transferred to antimicrobial-free medium in a 
biofilm recovery plate. Gentle centrifugation (805 g for 20 min) or a 5-min sonication at room 
temperature is used to transfer biofilms from the pegs to the plate. The MBEC values are then 
determined spectrophotometrically, by measuring the optical density at 620 nm. This method permits 
incubation of the biofilm with antimicrobials at different time-points, with daily rinsing and 
antimicrobial renewal [29]. 
It is important to point out that the minimal concentration of an antimicrobial required to 
eradicate a biofilm (MBEC) may be higher than the MIC determined against planktonic bacteria of 
the same species or isolate [3,9]. 
9. Biofilm prevention concentration  
Considerable efforts have also been devoted to prevent biofilm formation during the early 
stages of the colonization process [30,31], by effectively eradicating bacteria with the appropriate 
antimicrobial therapy [32]. The biofilm prevention concentration (BPC), defined as the antibiotic 
concentration required to prevent biofilm formation during the early stages of colonization, can be 
used to correlate in vitro measurements with the therapeutic results and may be a better indicator 
than other concentration-dependent parameters [21]. 
A modification of the MBEC assay can be applied to determine BPC values. A planktonic 
bacterial suspension is incubated in the CBD plates in growth medium containing different 
concentrations of antimicrobials [33]. After 4–24 h (depending on the specific bacterial growth rate) 
incubation, the pegs are rinsed, placed in antimicrobial-free medium in a biofilm recovery plate, and 
sonicated for 5 min. The detached bacteria are incubated for 4–24 h and the optical density (620 nm) 
is measured to determine the minimal concentration of antimicrobial preventing biofilm formation. 
Its well-established equivalence or similarity with the MIC, demonstrates the utility of the BPC 
in assessing antimicrobial-mediated reductions in bacterial density to prevent biofilm formation. Use 
of the BPC could also improve treatment strategies aimed at eradicating biofilm-producing bacteria 
already during early biofilm formation rather than at the mature biofilm stage. 
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10. Determination of bacterial viability in biofilms using confocal laser scanning microscopy  
A biofilm is a complex and multicellular structure that harbors physiologically distinct 
subpopulations of bacteria that together from a community able to adapt to rapidly changing 
environmental conditions [34]. The efficacy of an antibiotic with respect to biofilm viability, both 
over time and across the different layers of the biofilm, can be studied using CLSM [35,36]. In 
biofilms exposed to antimicrobial agents, CLSM reveals the effectiveness of the drug against the 
(metabolically active) outer layers and (metabolically attenuated) inner layers, and thus the 
time-dependent destruction of the biofilm. In an analysis of antimicrobial activity on P. aeruginosa 
biofilms, CLSM showed that some agents (such as ciprofloxacin) act preferentially on bacteria with 
high metabolic rates, whereas others (such as colistin) are effective only against bacteria with low 
rates of metabolism (Figure 6) [37,38,40]. 
To prepare the biofilm for CLSM, it is stained with a mixture of SYTO 9 and propidium iodide 
prepared at a dilution ratio of 1:2 (LIVE/DEAD Bac Light bacterial viability kit; Figure 6). Live 
bacteria stain green and dead bacteria red [41]. The CLSM images are then analyzed using ImageJ 
software (National Institutes of Health, Bethesda, MD, USA) [33] or other software tools. 
 
Figure 6. Confocal laser scanning microscopy images of P. aeruginosa biofilms stained 
using the LIVE/DEAD Bac Light bacterial viability kit. Green indicates viable bacteria, 
and red dead bacteria. (A) Most of the cells stain green, indicating a high level of 
bacterial viability. (B) Most of the cells are dead, indicated by their red fluorescence. 
Scale bar = 10 µm. 
11. Visualization of the effects of antimicrobials by atomic force microscopy 
Invented over three decades ago [42], AFM not only reveals details of the cell surface, but also 
allows biological samples to be mechanically mapped, touched, dragged, pulled, pushed, or indented 
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at the single molecular level. The resulting information provides valuable insights into the 
nanomechanical properties of living cells in their physiological environment and supports the 
information gained from other methodologies commonly used to assess antimicrobial activity, such 
as the MIC, minimal eradication assays, CLSM, and flow cytometry.  
AMPs alter the physical properties of the cell, specifically, their morphology, volume, surface 
roughness, and stiffness [43,44]. Data on roughness, obtained by software analysis, are 
complementary to viability assays. AFM analyses of the integrity of the cell surface and of 
membrane disruption can reveal whether treated cells display altered cell membrane characteristics, a 
loss of turgor, and a roughened surface, including bleb formation, with the eventual loss of the 
membrane permeability barrier and leakage of the intracellular content [45]. Imaging and the 
subsequent analysis of cell integrity have been used to evaluate alternative or complementary 
treatments.  
Gonçalves et al. [46] evaluated the antifungal activity of AMP Psd1, isolated from a defensin 
secreted by Pisum sativum, against three Candida albicans variants, one of them a mutant deficient 
in glucosylceramide synthase, conferring resistance to the peptide. AMP Psd1 significantly increased 
surface roughness, an indicator of relevant wall disorganization, resulting in a loss of stiffness of the 
treated cells of both the wild-type and the clinical isolate. Mularski et al. [47] used time-resolved 
AFM to study the pore-forming activity of the AMP Caerin 1.1 and its target. Adhesion forces, 
adhesion energy, the cell’s Young modulus and other physic-mechanical parameters can be extracted 
using AFM-force spectroscopy, through force-distance (F/D) curves. These describe the deflection of 
a cantilever when approaching and contacting the sample and the displacement along the z axis 
(Figure 7). 
 
Figure 7. Schematic representation of the different phases in a force-distance curve 
obtained from AFM force spectroscopy. The blue line corresponds to the approach trace, 
and the red line to the retraction trace. 
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As the cantilever approaches the cell (red trace in graphics), there are no changes in its 
deflection due to the absence of interaction forces at that point; however, when the tip reaches the 
sample, attractive forces such as Van der Waals forces, overcome the cantilever spring constant, 
forcing the tip to ―jump to contact‖ the sample. Variation during the retraction regime (blue trace) is 
often characterized by a prolonged extension due to the tip remaining in contact with the sample, 
such that the cantilever is reflected downwards. A ―jump‖ of the cantilever indicates its return to its 
final resting position. In terms of their nanomechanical properties, AMP-treated cells are less stiff 
than untreated cells [48], as shown by the final linear portion of the respective F/D curve. Moreover, 
the spring constant of the cell decreases in response to increasing AMP exposure, presumably due to 
the disintegration of the cell wall. Conversely, adhesion forces, generated between the tip and the cell 
surface, are considerably higher in AMP-treated cells. These forces represent the maximum external 
pulling force needed to separate the tip from the bacterial surface and the force needed to undo the 
recently formed bonds. Here again, degradation of the cell wall eases the penetration of the tip 
through the peptidoglycan layer and generates a higher number of contact points between them, 
finally increasing the force necessary to detach the cantilever from the cell [3]. As see in Figure 8, 
this force can either be continuous until detachment occurs or it can develop as several peaks, or 
jumps, of the pulling force towards zero when detachment is partial and bonds remain, a process 
referred to as sequential detachment. Finally, the adhesion energy is the sum of the amounts of energy 
needed to detach the AFM tip from the cell surface and to deform the cell close to its surface [49,50]. It 
is calculated by integrating the area under the detachment force curve over the z displacement. 
Pan et al. evaluated the interaction between the cell membrane and an AMP by studying the 
membrane lytic activity of a prion peptide (106–126). They reported decreases in both the Young 
modulus E of the bilayer and the bilayer puncture force, regardless of the cholesterol concentration 
of the supported lipid bilayers. In fact, a recent study by Henderson et al. showed that several AMPs 
reduce the edge stability of lipid membranes, thus altering the porosity of the cell membrane and 
causing the appearance of worm-like structures at high peptide concentrations. The specific 
interaction forces between AMPs and membrane components can be explored using single molecule 
force spectroscopy. This method was used by Oh et al., who characterized the nanoscale effects of the 
polycationic peptide polymyxin B (PMB) on bacterial membranes by determining the short-range 
interaction regime mediated by electrostatic forces between lipopolysaccharides and PMB, with 30 pN 
determined as the average unbinding force. 
These examples demonstrate the versatility of AFM as a tool for biomedical research that 
provides information on many topographic and nanomechanical parameters of microbial and 
non-microbial cells. 
12. Measuring the efficacy of antimicrobials against protozoa 
Protozoan parasites include the well-known genera Trypanosoma, Plasmodium, and Leishmania. 
These organisms cause several serious human diseases that hamper the lives of people mostly in 
developing countries. Thus far, the control and treatment of protozoan diseases has depended on a 
rather small number of antiparasite drugs, which are frequently highly toxic and of low efficiency. 
Moreover, resistance of the parasites to these drugs is becoming increasingly common [51]. Thus, 
novel compounds and/or strategies are needed, including delivery systems [52] and new molecules, 
such as AMPs [53]. Membranes and DNA topoisomerases have attracted considerable interest as 
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potential targets for novel antiparasitic therapeutics [54,55]. 
 
Figure 8. Representation of the retraction of the cantilever and the associated adhesion 
forces. As the cantilever moves away from the sample, the tip and surface molecules can 
detach in different ways. The adhesion force corresponds to the maximum external 
pulling force necessary for detachment to occur. On the right: Schematic representation 
of the different phases in a force-distance curve obtained from AFM force spectroscopy. 
The blue line corresponds to the approach trace, and the red line to the retraction trace.  
With respect to AMPs, protozoa have received less attention than other microorganisms; 
however, they may be readily accessible targets because, except in the resistant cyst stage, they do 
not present structured external barriers, such as the bacterial capsule, the outer membrane of 
gram-negative bacteria, the thick peptidoglycan layer of gram-positive bacteria, or the compact 
fungal wall. The absence of these barriers allows direct interactions between the parasite and the 
AMP, which could facilitate an interpretation of the results. Nonetheless, in addition to determining 
the biocidal power and therapeutic index of an anti-protozoal therapeutic, its mechanism of action, 
lethal activity, and other effects, such as membrane permeation or modification of the energetic 
parameters of the parasite, must be elucidated to obtain valuable information on other potential 
targets as well as further drug development. 
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How AMPs perturb and destroy parasites can be studied using AFM, to examine morphological 
and structural damage of the cell surface, and transmission electron microscopy, to assess structural 
modifications to the parasite. The topographical relationship of the parasite with the AMP and the 
identity of intracellular targets, including the induction of apoptosis, can be investigated using 
confocal microscopy (see below). However, most protozoa have complex life cycles involving 
intracellular stages. Thus, as a first step, AMP activity should be assessed in extracellular parasites, 
before time-consuming and labor-intensive intracellular tests are performed.  
Methods used to examine the efficacy of an AMP against a parasite include the following: 
Cell proliferation measurements: As cell counting is tedious and subject to bias arising from 
reader expertise, fatigue, etc., the staining of viable cells using chromophores such as MTT, XTT, or 
resazurin allows an automated, colorimetric, and quantitative measurements of viable cells. 
Cytotoxicity against intracellular parasites: The direct examination of mammalian cells stained 
with Giemsa’s azur-eosin methylene blue reveals those infected with the parasite. A minimum count 
of 200 cells from different fields is required; the results are expressed as parasites per cell. 
Assessment of plasma membrane permeation: The interaction between AMPs and the plasma 
membrane phospholipids of the target cells has been well-documented. For many AMPs, the peptide 
inserts into the membrane, disrupting its integrity and therefore its function as a permeation barrier, 
resulting in a lethal loss of internal homeostasis. For other AMPs, lethality is produced intracellularly, 
after their translocation across the membrane. Plasma membrane integrity can be assessed using 
fluorescence techniques, including cationic stains such as Syto9 or propidium iodide. Both of these 
vital dyes bind intracellular nucleic acids such that their entrance into the cell implies severe 
membrane damage, as also described in bacteria. Small or transient membrane damage results in 
plasma membrane depolarization, which can be followed using the sensitive probe bisoxonol, an 
anionic fluorescent molecule that reveals the discrete permeation of ions able to dissipate ion 
gradients. Mitochondrial membrane depolarization can be investigated based on the differential 
accumulation of rhodamine 123, a cationic fluorescence dye that enters metabolically active 
mitochondria. 
Confocal microscopy: Using this technique, cells stained with different simultaneous labels can 
be examined and the intracellular target of a fluorescently labeled peptide identified. For example, 
organelles can be selectively stained and their distribution pattern compared with that of the tagged 
peptide. Among the fluorophores used for confocal microscopy are AMPs labeled with fluorescein, 
MitoTracker red (mitochondrial staining), and DAPI (nuclear and kinetoplast dye).  
Measurement of the oxygen consumption rate: If oxidative phosphorylation, rather than 
glycolysis, is the main source of energy for the parasite, then dissolved oxygen, as an indicator of 
oxygen consumption, can be measured, typically using a Clark electrode or, as done traditionally, 
Warburg’s instrument [56].  
Microscopy. As in bacteria, the visualization of morphological alterations in parasites confirms 
antimicrobial action. Ultrastructural alterations of parasites can be viewed using transmission 
electron microscopy, and the three-dimensional surface morphology of the organisms using AFM. 
Sample treatment form AFM is minimal and the cells remain viable so that they can be evaluated 
physiologically in parallel. 
Assessment of apoptosis by flow cytometry. Sublethal concentrations of peptides tend to cause 
apoptosis rather than necrosis, induced by higher doses. Apoptosis also occurs in response to slow 
permeation of the AMP or when the target is not the membrane but an intracellular organelle. Cell 
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cycle analysis by flow cytometry, based on separation of the cells according to their DNA content, is 
a fast and easy method to study apoptosis. Ethanol-fixed, permeabilized protozoa are stained using 
propidium iodide and apoptotic cells then identified based on the appearance of characteristic peaks 
on the resulting histogram.  
13. Evaluation of the antifungal activity of AMPs 
Procedures to evaluate novel antifungal peptides are similar to those described above for 
antimicrobial peptides. However, as yeast and molds are eukaryotes, important differences involving 
nutritional requirements, optimal temperature, and duplication rate must be considered.  
Standardized protocols for both yeasts and molds have been developed by the CLSI [57,58] and 
EUCAST [59,60]. In the case of the microdilution method, the main difference between the protocols 
of the two institutions involves the end point, based on the extended duplication time of these 
microorganisms. The CLSI use the same protocol developed for prokaryotic cells but with a 48-h 
incubation time, while in the EUCATS protocol results are obtained spectrophotometrically at 24 h. 
The MIC is defined as the lowest concentration resulting in a 50% (90% in some cases) inhibition of 
growth compared with the control.  
Dynamic studies on the interaction between drugs and fungi should be performed as described 
for bacterial strains, albeit with differences in terms of the appropriate medium (RPMI), the 
inoculum size, and an extension of the incubation time up to 48 h. 
The method to determine the antibiofilm activity of an antifungal agent differs from the 
bacterial protocol mainly in how the results are read. Similar to BPC and MBEC determinations for 
bacteria, the metabolic activity of fungi is measured using XTT or resarzurin [61] and the resulting 
tetrazolium compound monitored spectrophotometrically. However, for yeasts and molds, the BPC 
and MBEC are defined as the lowest concentration of the drug that yields a 90% reduction in 
metabolic activity vs. the untreated control. 
Other techniques to study antifungal activity are being introduced. Of particular interest is flow 
cytometry [62]. The cells are stained with two different fluorescent dyes, one of which penetrates 
normal or intact cells, and the other only cells with a disrupted membrane, i.e., dead cells. Flow 
cytometry allows for single-cell fluorescence investigations. Hence, after the analysis of a suspension 
of cells treated with the antifungal peptide, a count of live and/or dead cells is obtained. The major 
advantages of this technique are the ability to study a large population of cells and the speed of the 
cell-by-cell analysis. 
14. Remarks 
In summary the antimicrobial effect of a new molecule should be assessed in several steps, 
which are summarized in the flow chart shown in Figure 9. 
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Figure 9. Sequence of techniques to be done at the initial search of new AMPs. 
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Discussion
Colistin and related molecules have been reported tobe synergistic with other antimicrobials, particularly with
carbapenems in Acinetobacter baumanii, as well as in Pseudomonas
and a few other Gram-negative bacteria. In principle resistance to
carbapenems is mostly caused by impermeabilization of outer layers
in microbial envelopes to the antibiotic molecule. Imipenem used
the porin OprD to penetrate Pseudomonas.
As pointed out, when used together, combinations of
colistin and imipenem gave a FICi of 0.625 for P. aeruginosa ATCC
27853; such a value is close to 0.5 which is the value considered
as indifferent when using the recommendations of Journal of
Antimicrobial Chemotherapy (JAC). Using other criteria such a
value may be interpreted as additive. Despite the recommendations
of JAC are the most restrictive ones, in our work we have
used them. Moreover, when such combinations were assayed
in other strains and isolates, particularly when experiments were
performed with AMP38, the FICi value reached values as low as
0.625 a value identical to the one determined with colistin and
imipenem. This suggests that both AMP38 and colistin act in
a similar manner on this imipenem-susceptible strains. It should
be emphasized that, in principle, the entry of imipenem in fully
susceptible bacteria is not prevented by the outer membrane, since
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OprD is functional and can allow the penetration of imipenem to
the periplasmic space, and subsequently, the antibiotic can reach its
target easily. On the contrary, when acting on imipenem-resistant
bacteria (in which the permeability to carbapenems is altered due
to the loss or alteration in the expression of proteins (porins)
towards which ones carbapenems may penetrate outer membrane
to reach periplasmic space, the combination of imipenem and
AMP38 gave FICi values below 0.5; this is to say they act in a
synergistic way. In other words, when imipenem may not entry the
bacterium, colistin and analogues will facilitate such an entry. These
values indicate and should be regarded as strongly synergistic (paper
1 table 2). For instance, strain PA116136 is imipenem-resistant, since
its OprD gene is knocked out by the presence of an insertion
sequence ISPa133 we described a few years ago (Ruiz-Martinez et
al).181 Other resistant strains used in this work, are OprD defective.
That is to say they have lost OprD gene probably as a result of
selective processes in patients treated with imipenem. Subsequently,
the entry of imipenem is strongly limited in standard culture
conditions for all these bacterial strains. This is the main (if
not the unique) reason why these bacteria are fully resistant to
imipenem.
In that way, the synergism between the colistin-inspired
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peptide and the carbapenems should only be interpreted as a
consequence of the ability of peptides to overtake the limitations
in the imipenem entry, since colistin-derived molecules have not
enough antibacterial power as to eradicate these bacteria. It seems
feasible that they may open ways by which imipenem is going to
reach their target molecules (PBPs) this is the reason why we call
such molecules “door openers”. Similar results were obtained when
identical experiments were performed with the rest of resistant
strains lacking OprD. Moreover, these results pointed out that
the disorganization and injuries in the outer membrane caused by
AMP38 (and other polycationic peptides inspired in colistin) seem
to facilitate the entry of imipenem to the periplasmic space.
As a parameter, FICi values have certain limitations. In
one side the value is simplified; they do not give information
about the kinetics of bacterial killing. The results are determined
after 24 h exposure to antimicrobials, and thus represent a fixed
picture of the state after the incubation period. This is a
limitation widely extended in parameters measuring the antimicrobial
action. For instance, MIC values have an actually similar limitation.
Consequently, with this type of assay, one could disregard the
eventual usefulness of antimicrobial combinations for the treatment
of complicated microbial infections. If a given combination may
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eradicate bacteria during the first four hours incubation, allowing to
survive a small proportion of the bacterial population which, when
selective antibiotic pressure finish, will generate a new population
(re-growth phenomenon) will never be considered as presumably
useful if information comes exclusively from FICi or MIC. This
make necessary to explore the process along the incubation period.
In consequence, we have performed series of experiments in order
to explore the antimicrobial actions during the first steps of the
growth cycle. Combinations of sublethal concentrations of colistin
combined with the appropriate concentrations of imipenem failed
in increasing bacterial death. On the contrary, the 4 µg/mL
concentration of colistin combined with either 0.5 or 4 µg/mL
of imipenem markedly enhanced death. These results resulted to
be imipenem concentration independent; this is consistent with the
hypothesis that colistin facilitates the entry of carbapenem, and
that eventual resistance would be due to restrictions in the access
of imipenem to PBPs (Paper 1, Figure 2A). The reason is not
new, but the proposal to use colistin analogues to facilitate the
imipenem penetration is one of the main proposals of this work.
Combinations of AMP38 behavior changes depend on
concentrations assayed. Thus, in general it may be stated that
imipenem enhances bacterial death. Nevertheless, whereas 8 µg/mL
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of AMP38 alone had a bacteriostatic effect, the combination of
AMP38 (also at 8 µg/mL) plus imipenem (4 µg/mL) resulted in a
bactericidal effect despite the fact that the MIC of imipenem is
16 µg/mL and that of AMP38 is 32 µg/mL. That is to say, when
acting together MIC decreases up to six-fold. It should be stated
that the combination failed to completely eradicate the bacterium,
and regrowth appear after long periods of incubation (Paper 1,
Figure 2C). Meropenem at 1 µg/mL had a bacteriostatic effect,
keeping bacteria at 107 CFU/mL. Nonetheless, the combination
of 4 µg/mL of AMP38 plus 1 µg/mL of meropenem completely
killed bacteria after 6 h of contact.
On the basis of the initial assumption that the mechanism
of cooperation between the different antimicrobials used in this
thesis, recommended the performance of some more experiments.
Time kill-kinetics with sub-lethal concentrations of imipenem and
AMP38 and assays performed with meropenem (Paper 1 Figure
2D), as well as those carried out at low (sublethal) concentrations
of both AMP38 and imipenem and several combinations of
both (Figure 2 E,F) confirmed that AMP38 facilitates the entry
of imipenem by disturbing the outer membrane, confirming the
previous hypothesis. In the Figure 3 of paper 1 the effect on the
mucous 023VH strain growth curve is shown. It may be seen to
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be very similar to the results obtained with the rest of strains
studied.
As pointed out for many authors, biofilm constitutes one
of the main challenges of modern microbiology. One of the main
goals of antimicrobial chemotherapy is the eradication of biofilms.
Stable biofilms can play a key role in pathogenesis, and this is
particularly a matter of concern in respiratory infections caused by
P. aeruginosa and some other respiratory pathogens such as Klebsiella
pneumoniae.
P. aeruginosa is able to produce stable biofilms in many
environmental conditions, this is particularly apparent when the
bacterium is causing lung infections. Sessile bacteria living in
a biofilm state are regarded as generally more resistant to
antimicrobial agents. Nevertheless, in some species it has been
impossible to demonstrate differences in antimicrobial susceptibility
between sessile and planktonic individuals. Since biofilm is so
relevant in Pseudomonas pathogenicity, the exploration of ways to
remove biofilm acquire a central interest. In consequence, the
ability of combinations of AMP38 and imipenem to eradicate
biofilms was explored. In our experience the use of colistin to
eradicate biofilms needs concentrations higher than 1000 µg/mL;
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imipenem’s MBEC is higher than 500 µg/mL, whereas the
combination of AMP38 and imipenem was able to completely
eradicate the biofilm at 62.5 µg/mL. Thus, a true synergism of
imipenem and AMP38 was again observed when the parameter
measured was the ability to remove biofilm.
Electron microscopy and particularly TEM has greatly
contribute to decipher structural details of microorganisms allowing
significant advances in the understanding of bacterial structure and
eventually their physiology, including antibiotic tolerance and biofilm
formation. The mechanism of action of AMP38 in P. aeruginosa
and S. marcescens was confirmed by examining untreated and
treated bacteria with transmission electron microscopy. Untreated
P. aeruginosa cells were examined by TEM. Electron micrographs
of AMP38-treated P. aeruginosa (Paper 1, Figure 4) show a
disorganized outer and inner membrane, as compared to the
smoothness of untreated membranes. As a control, S. marcescens
was used, since our group has a long expertise in using colistin
in the naturally-resistant species such as S. marcescens (Lauferska et
al.)182 This bacterium is intrinsically resistant to colistin since no
alterations in viability may be seen when it is incubated in colistin
presence, although colistin disorganizes its outer membrane, but
it seems that it is not capable of altering the inner membrane,
119
Synthetic polymyxin-based peptides against multidrug resistant bacteria: a therapeutic option
and subsequently the bacterium remains viable. Typically, the effect
of colistin on S. marcescens cells is visualized as the production
of blebs. We performed an ultrastructural analysis via TEM in
order to explore whether colistin and AMP38 share mechanisms of
action.
When S. marcescens is exposed to colistin, blebs appeared on
the outer layer, but no changes were visualized in the cytoplasmic
membrane. Paper 1, Figure 4 shows S. marcescens exposed to the
AMP38, where blebs were observed in the outer membrane being,
at least morphologically, identical to the ones caused by colistin.
Although further research has to be done, the microscopically
visualized effects of AMP38 and colistin on Gram-negative bacteria
seem to be similar, if not identical. This is also consistent with
the phenomenon of synergism described in this work.
In conclusion, our data pointed out that the use of
synthetic AMPs inspired by natural products that are potentially
less toxic than the natural parent compounds, may contribute
to the rescue of antimicrobial agents to which some pathogens
have become resistant. If combinations allow the use of toxic
antimicrobials at much lower concentrations, taking into account
that toxicity is in all cases dose-dependent and in some cases
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(as it happens with colistin) a result of the accumulation of
antimicrobial molecule in organs along the treatment, will allow
a much safer use of old and “toxic” antimicrobial agents. In
this case, it seems feasible to kill imipenem-resistant Pseudomonas
aeruginosa with imipenem (apparently a paradox) when combined
with other molecules (such as AMP38) which are able to sensitize
the bacterium to the antibiotic. Since carbapenems remain the main
antimicrobials for treating multidrug-resistant P. aeruginosa infections,
and the development of carbapenem resistance may significantly
compromise their efficacy, the use of peptides such as AMP38
could serve to rescue the use of carbapenems for these purposes.
Their use should give better results than the use of colistin and
polymyxins, which have already demonstrated synergistic effects.
During the development of this PhD thesis series of
AMPs were synthesized. Two of them were selected due to
their antimicrobial activity. Peptides CAMP113 and CAMP207
have also a disulphide bonds between the two cysteine residues.
They are similar to colistin although with some significant
differences. Moreover, they contain a dodecanoyl chain instead
of (S)-6-methyloctanoyl, have a Cys residue at position 4,
norleucine (NLe) at position 7 and (D)-Cys at position 11,
instead of 2,4-diaminobutyric acid, Leu and Thr of polymyxin.
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CAMP113 was further modified with (D)-Phe and CAMP207 with
(D)-(4F)-Phe instead of Leu at position 6. In addition, an Arg
was substituted at position 8 of CAMP113 whereas colistin contains
2,4-diaminobutyric acid (Paper 2, Figure 1). As it has been
stated, Polymyxin action involves interaction with lipid A and the
displacement of Mg2+ and Ca2+ bridging adjacent LPS molecules.
In routine experiments we tested a few Gram-positive strains.
Surprisingly, both AMPs resulted to be active on Staphylococcus
tested strains. The MIC of both peptides was of 4 µg/mL. Tested
strains were as expected resistant to colistin (higher than 512
µg/mL), this is generally accepted since Gram-positive bacteria are
regarded as fully resistant to polymyxins. On the other hand, all
tested Gram-positive strains were susceptible to vancomycin (1–0.5
µg/mL). Then, a vancomycin-resistant strain was obtained from the
“Centro Nacional de Microbiolog´ıa, Majadahonda”, Madrid Spain,
Lab of Dr. Sa´ez-Nieto; this is the SasVR strain (paper 2, Table
S1). The activity of the two CAMPs was actually high, their
MICs being more probably within the clinical use range. As we
pointed out before, MIC values represent only the cumulative
effect after 18 h incubation, rather than the time course of
activity, whereas time–kill kinetics or growth curves describe the
antimicrobial action, providing insights into the events during
its first hours and depicting the biological behavior over time.
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As expected, based on their chemical similarities both peptides
killed the bacteria in a concentration-dependent manner (Paper
2, Figure 2), their behaviour being very similar irrespective of
the strain tested. Two types of responses were observed in the
presence of CAMPs: either the bacterium was completely inhibited
at all concentrations tested or inhibition was achieved only at
high concentrations (Figure 2). Neither peptide was able to fully
eradicate the bacteria solely as a function of its concentration;
rather, the activities of the two CAMPs strongly depended on the
bacterial strain. For example, CAMP113 was able to fully eradicate
the strain SaS06 (paper 2 Figure 2a) in a time as short as 1 h
when acting at a concentration of 16 µg/mL and in 2 h at 8
µg/mL. However, a few bacterial individuals were able to survive
at lower concentrations (4 µg/mL). In contrast strain SaS16 was
completely eradicated at this latter concentration (Paper 2, Figure
2). At a concentration of 8 µg/mL or higher, CAMP113 produced
the rapid death of strain SaS16 (paper 2, Figure 2c) during the
first hour whereas at an equal concentration of CAMP207 (Figure
2) 2 h were required. At 4 µg/mL, both peptides required 4 h
to fully kill the cultures of strain SaS16. In experiments made
with strain SaS18, a complete eradication was achieved within 4 h
when using 8 µg/mL CAMP113 but within 6 h when using the
same concentration of CAMP207 (Figure 2f). However, even at
123
Synthetic polymyxin-based peptides against multidrug resistant bacteria: a therapeutic option
4 µg/mL, CAMP207 completely failed to eradicate SaS18. Similar
outcomes were obtained with the remainder of the tested strains.
Paper 2, Figure 2 also shows representative growth curves.
With inocula up to 2 x 106 CFU/mL, the growth was fully
prevented by both CAMPs irrespective of the concentration tested
(4, 8 or 16 µg/mL). In contrast higher inocula (up to 2 x108
CFU/mL) gave initial growth delays when acting at 4 µg/mL, and
a longer delay at 8 µg/mL. Finally, both CAMPs were able to
fully inhibit the growth at concentrations of 16 µg/mL when using
the bigger inoculum, demonstrating once again the concentration
dependence.
S. aureus have evolved mechanisms to evade innate host
defenses including proteolysis of natural peptides, secretion of
lytic enzymes, modulation of the electrical charge of the cell
surface to enhance repulsion, and biofilm formation. As we
pointed out before, biofilms have been the focus of considerable
research attention and their destruction the main goal of current
antibacterial therapy. The MBECs of both CAMPs indicated the
ability of these compounds to eradicate fully the S. aureus biofilms
at relatively low concentrations, in contrast to colistin, which had
no effect. Confocal imaging (Paper 2, Figure 3) revealed the effects
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of the CAMPs (at 128 µg/mL) on S. aureus biofilm during short
exposure periods (4 h). As expected no significant death occurred
in the controls nor in colistin-treated biofilms, whereas CAMP113
and CAMP207 were able to kill roughly one-half the bacteria
within the biofilm (47.27% and 50.46%, respectively).
Given the current interest in CAMPs in the search for new
approaches in anti-biofilm treatment, our study demonstrates the
capability and potency of these peptides in targeting biofilms of
several clinical isolates of S. aureus. This open new perspectives in
the use of AMPs as antibiofilm agents. In fact, under conditions
in which a colistin dose of 2048 µg/mL was required to eradicate
biofilm, both CAMP113 and CAMP207 were able to reach the
same result (eradication of the biofilms of all strains tested) at
much lower concentrations (Paper 2, Figure 3).
The use of new molecules in clinics requires a deep
knowledge of their toxicological effects. CAMPs herein studied
were tested for their cytotoxicity in the human hepatocellular cell
line HepG2 (ATCC HB8065). Despite such an experiment is not
enough to jump to the clinical use, preliminary experiments in this
field are an indicator of the presumably expected interest. That is
to say, if preliminary toxicological experiments demonstrate a high
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toxic power the product may be discarded. As shown in Figure 4,
colistin had relative low cytotoxicity in vitro as its mechanism of
toxicity involves the accumulation of molecules in organs such as
the kidney and others. At 5 µg/mL, a slightly higher concentration
than the MICs of the CAMPs, none of the tested compounds
had detectable toxicity. A concentration of 50 µg/mL yielded
89.49% HepG2 cell viability for colistin and 67.03% and 62.62%
for CAMP113 and CAMP207, respectively. At 100 µg/mL, colistin
resulted in 68.75% HepG2 viability, CAMP113 53.2% and CAMP207
57.3%. At an antimicrobial concentration of 250 µg/mL, HepG2
viability was 51.05%, 16.01% and 8.29%, respectively. At 500 µg/mL,
whereas 38.39% of the cells survived in the presence of colistin
both CAMP113 and CAMP207 were highly toxic (7.74% and 7.4%,
respectively) (Paper 2, Figure 4). None the less, the selectivity
index (the relationship between the IC50 and the MIC)183 in S.
aureus strains was inordinately high for the peptides (21.25 for
CAMP113 and 23.75 for CAMP207 compared with 0.36 for colistin),
i.e. CAMP113 and CAMP207 are much more selective than colistin
because the concentrations needed to kill the bacteria are much
lower. Moreover, colistin is nephrotoxic, as it increases tubular
epithelial cell membrane permeability to cations, anions and water,
leading to cell swelling and cell lysis.184 The presence in the
newly synthesized CAMPs of a disulphide bond facilitates their
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biodegradation and thus avoids their accumulation in the kidney.
This is in agreement with previous studies, in which the LD50
for peptides of this family in CD-1 mice was 283 mg/kg, compared
with the 59.5 mg/kg determined for polymyxin.179
The emergence of MDR strains of several species has posed
a tremendous challenge in clinical practice and renewed interest in
polymyxins, whose activity against Gram-negatives is well established.
Colistin is considered the drug of last resort in the treatment of
Gram-negative MDR bacteria such as P. aeruginosa, A. baumannii and
Klebsiella pneumoniae.185 None the less polymyxins are intrinsically
inactive against Gram-positive bacteria because these bacteria lack
outer membrane and consequently lipid A, which is the the
primary binding site for all polymyxins. Novel peptides herein
studied, despite they were synthesized in an attempt to evade the
increasing polymyxin resistance of Gram-negative bacteria resulted to
have low MIC values in Gram-positive organisms showing good
activity against S. aureus.
In an attempt to explain such an activity, we did a search
of molecules in Gram-positive organisms which may mimic the
chemical structure of Lipid A. In figure 6.1 there is a reproduction
of figure of the article (Velkov et al.)186 in which a model of
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colistin-lipid A binding is presented.
Figure 6.1: Molecular models of the complex between polymyxin B
and the lipid A structure from Klebsiella pneumoniae. From Velkov
et al.186
In figure 6.2 chemical structure teichoic acids is provided.
Based on the apparent similarities between both formulas we have
hypothesized that teichoic acids may act as primary receptors for
pour colistin-like CAMPs. To determine whether teichoic acids were
such targets for CAMP113 and CAMP207, we performed isothermal
titration calorimetry experiments. The results showed a three-step
reaction between the peptides and teichoic acid, two of which were
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exergonic and the third endergonic (Paper 2 Figure S1). To examine
the spectrum of action of the CAMPs studied, we explored their
action against Gram-positive Streptococcus pneumoniae.
Figure 6.2: Teichoic acid molecule
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Our results showed that in these species the MIC of
colistin was consistently 32 µg/mL, whereas the MICs of both our
peptides were between 2 and 4 µg/mL depending on the isolate.
Polymyxins, regarded as inactive against Gram-positive organisms,
after some small changes, have activity against S. aureus and S.
pneumoniae; subject to more detailed determination of in vitro and
in vivo toxicity as well as the development issues, peptides of this
type may open up new frontiers in the treatment of “untreatable”
infections.
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Conclusions
1. Combinations of colistin and imipenem are indifferent
in imipenem-susceptible strains and strongly synergistic in
imipenem-resistant strains.
2. Synergism between CAMPs and imipenem lies on the ability
of CAMPs to open ways through both sides of outer
membrane which are going to be used for carbapenems to
penetrate.
3. AMP38 alone has a bacteriostatic effect, at low concentrations
while the combination of AMP38 plus imipenem result in a
bactericidal effect.
4. A true synergism of imipenem and AMP38 exists able to
remove biofilm of P. aeruginosa.
5. It is feasible to kill imipenem-resistant Pseudomonas aeruginosa
with imipenem (apparently a paradox) when combined with
AMP38.
6. AMP38 disrupts outer membrane of Gram-negative bacteria.
7. CAMP113 and CAMP207 result to be active on
Staphylococcus aureus. Both peptides kill the bacterium in a
concentration-dependent manner, bacterial death also strongly
depended upon the initial inoculum.
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8. Both CAMPs (113 and 207) have the ability to fully eradicate
Staphylococcus aureus biofilms.
9. The selectivity index in Staphylococcus aureus strains is
inordinately high for the peptides CAMP113 and CAMP207
compared with colistin.
10. Isothermal titration calorimetry experiments strongly suggest
that teichoic acids are the primary receptor for colistin-like
peptides.
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APPENDIX

Appendix
During the course of this doctorate we succeed in
characterising antimicrobial peptides synthesized by in Organic
Chemistry Faculty of University of Barcelona. There, I learnt
the basic principles of biomolecule synthesis, carrying out solid
phase synthesis technique. All peptides studied in this PhD thesis
were synthesized using manually standard Fmoc/tBu procedures.
Moreover, chromatography techniques were used in order to
characterize peptides.
1.1 Background
Emil Fisher was the first in synthesize a protein
(glycyl-glycine) in 1901, checking that the amino acids were
linked together by the link peptide. Technique evolution was very
slow because of it should protect amino acid group to avoid
self-linking. Finding a compound able to block amino group and
able to be removed easily after link peptide formation do not
achieve until 1932 by Max Bergamnn y Leonidas Zervas. Moreover,
another handicap was to isolate the peptide and obtain a relatively
high yield.
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1.2 Synthesis
1.2.1 Protective groups
Protecting functional groups is one of the main steps in
peptides synthesis in order to avoid that carboxyl group reacts with
amino group of the same amino acid. In addition, amino acid
side chains must be protected because they are able to react with
carboxyl group and/or amino group as well. One of the most
used group to protect α-amino group is fluorenyl-9-methoxycarbonyl
(Fmoc) which is very stable in the presence of acids and in
addition it can be removed in light basic conditions such as 20%
piperidine in dimethylformamide (DMF).
CH2
H
O C
O
NH
HN
CH2 O C
O
NH2 C NH
O
-O
NH2
CH2
H2
C
H
N
HN
H+
CO2
Figure 1.1: Fmoc deprotection
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Carboxyl group it is not mandatory to protect due to it
is less nucleophilic. Nevertheless, it is convenient to protect it in
order to increase peptide solubility in organic solvents. Moreover,
it is important to block carboxyl group which is nor forming part
of the peptide link whereas the one that participates in the link
must be unprotected ready to be activated. For this purpose, we
used t-butyl ester technique.
Figure 1.2: tbutyl ester deprotection
1.2.2 Peptide bond
Peptide bond is an endergonic reaction, addition of carboxyl
acid with an amine will result in the correspondent organic salt.
However, peptide bon consist in an amide, thus it is mandatory
to activate carboxyl group. This reaction is called aminolysis and it
is necessary an electrophilic activating agent (X).
v
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Figure 1.3: amide bond formation
1.2.3 Solid phase synthesis
The principal idea of the solid phase synthesis is based on
anchoring the growing peptide by C-terminal to an insoluble solid
support. Wherewith, peptide elongation occurs in several cycles of
unprotect and attach of amino acids. Here, there is a scheme of
the procedure.
One of the most important steps in solid phase synthesis is
the anchor a molecule called “linker” to the resin. Usually, linkers
are bifunctional molecules which attach permanently to the resin by
a amide bond, and the other side they attach temporarily to the
growing peptide by a ester bond. This linker should be very stable
in order to withstand deprotection reactions but at the same time
should be easily to detach to the resin when reactions finish. Some
likers are: 4-hydroxymethylbenzoic acid, methoxy-4-hydroxymethyl
benzoic acid or 1,3dimethyl-4-hydrozymethylbenzoic acid.
vi
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Figure 1.4: solid phase synthesis scheme
vii
Synthetic polymyxin-based peptides against multidrug resistant bacteria: a therapeutic option
Once peptide is synthesized and detached from resin, it is
cycled by two cysteine residues to form a disulphide bond. Finally,
peptide is purified by HPLC and characterized by MALDI-TOF.
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